

Curriculum Vitae

BYUNG HA CHUNG, MD, PhD

GANGNAM SEVERANCE HOSPITAL
Yonsei University College of Medicine, Department of Urology
211 Eonjuro, Gangnam-gu, 06273
Seoul, Republic of Korea

Telephone: +82-2-2019-3474

Cell phone: +82-10-8191-5807

Fax: +82-2-3462-8887

E-mail: chung646@yuhs.ac

BORN Seoul, Korea
30th December, 1959

CITIZENSHIP Republic of Korea

APPOINTMENTS

1991 - 1994	Full time Instructor, Department of Urology, Gyeongsang National University College of Medicine
1994 - 1995	Assistant professor, Department of Urology, Gyeongsang National University College of Medicine
1994 - 1995	Visiting Clinician, Mayo Clinic, Rochester, MN, USA
1995 - 2001	Assistant Professor, Department of Urology, Yonsei University College of Medicine
1999 - 2000	Research Fellow, Mayo Clinic, Rochester, MN, USA
2001 - 2006	Associate Professor, Department of Urology, Yonsei University College of Medicine
2008 - 2009	President, The Korean Prostate Society
2010 - Present	Chairperson, Urologic Cancer Clinic, Gangnam Severance Hospital
2011 - 2013	President, Severance Urology Oncology Group (SUOG)
2012 - 2014	President, Asian-Pacific Prostate Society
2010 - 2020	Chairperson, Department of Urology, Gangnam Severance Hospital Yonsei University College of Medicine

2014 – 2018 Chairperson, Department of Urology, Yonsei University College of Medicine
2012 - Present Executive member, The Korean Urological Oncology Society

EDUCATION AND TRAINING

UNDERGRADUATE

1978 - 1980 Premedical Course
Yonsei University College of Natural Science

MEDICAL

1980 - 1984 B.M.S., M.D.
Yonsei University College of Medicine

POST GRADUATE TRAINING

1984 - 1985 Internship Program
Severance Hospital, Yonsei University College of Medicine

1985 - 1988 Residency Program
Severance Hospital, Yonsei University College of Medicine

1988 - 1991 ROK Army physician, Military Service

1985 - 1987 M.M.S. Yonsei University Graduate School

1991 - 1994 Ph.D. Yonsei University Graduate School

LICENCES & SPECIALTY BOARDS

February 1984 National Medical Licensure Examination (No. 27517)
Ministry of Health and Social Welfare, Republic of Korea

March 1988 Diplomate, Korean Board of Urology (No. 646)
Ministry of Health and Social Welfare, Republic of Korea

MEMBERSHIPS

Korean Medical Association
Korean Urological Association
Korean Cancer Association

Korean Urologic Oncology Society
Korea Prostate Society
American Urological Association
Asian-Pacific Prostate Society

AWARDS AND SPECIAL HONORS

1. The 7th Outstanding Science and Technology Research Honor. The Korean Federation of Science and Technology Societies, 1997. **Chung BH.**
2. The Korean Prostate Society Outstanding Research of the Year. Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia: an observational cohort study. 2003. **Chung BH.**
3. The Korean Prostate Society Outstanding Research of the Year. Can a 12 core prostate biopsy increase the detection rate of prostate cancer versus 6 core: a prospective randomized study in Korea. 2005. **Chung BH.**
4. Outstanding Clinical Professor of the Year. Severance Hospital, Yonsei University College of Medicine. 2006. **Chung BH.**
5. Outstanding Research Professor of the Year, Yonsei University College of Medicine. 2010. **Chung BH.**
6. The Korean Urology Association Annual Congress Video Session Award. 2011. **Chung BH.**
7. The Korean Prostate Society Oral Presentation Award. Predictive signs of postoperative inguinal hernia in the internal inguinal floor. 2012. **Chung BH.**
8. The Korean Prostate Society Annual Research Award. Is it suitable to eliminate bone scan for prostate cancer patients with PSA \leq 20 ng/mL? 2012. **Chung BH.**
9. American Urological Association(AUA) annual meeting Best Abstract. Non visible tumor on multiparametric MRI would not predict the low risk prostate cancer. 2014. **Chung BH.**
10. The Korean Urological Association (KUA) Most Outstanding International Publication Award. A simple procedure to prevent postoperative inguinal hernia after robot-assisted laparoscopic radical prostatectomy: a plugging method of the internal inguinal floor for patients with patent processus vaginalis. 2014. **Chung BH.**

BOOK

A Guide to Prostate Cancer Cure, Health Chosun, 2012. Chung BH.

A Guide to Prostate Cancer Cure (New Version), Health Chosun, 2019. Chung BH.

BOOK CHAPTER

Textbook of Urology, 4th edition, 2007, Chapter 15.5. Prostate Cancer. The Korean Urological Association.

Management of Advanced Prostate Cancer, 2018, Chapter 22, Radiopharmaceutical Therapy in Metastatic CRPC, Springer.

SUPERVISION

GRADUATE STUDENTS

- 2004 Lee JS, Associate professor, Kwandong University, Department of Urology, The effect of Ureaplasma urealyticum Mycoplasma hominis in Semen on Sperm Analysis Parameters.
- 2005 Lim YJ, Clinical fellow, Yonsei University, Department of Urology, Can prostate specific antigen predict the prostate growth?
- 2007 Bang WJ, Associate professor, Hallym University, Department of Urology, Perioperative morbidity of elective or emergent TURP as a treatment of benign Prostatic Hyperplasia
- 2007 Ko WJ, Ilsan Hospital, The effect of Resiniferatoxin injection on rat's prostate
- 2009 Choi HM, Sunggong Urologic Clinic, Comparison of urinary symptoms according to the classification of SS-penogram in patients combined with erectile failure and lower urinary symptoms
- 2011 Lee SH, Associate professor, Yonsei University, Department of Urology, Effects of alpha blocker "add on" treatment on blood pressure insymptomatic benign prostatic hyperplasia with or without concomitant hypertension
- 2011 Kim KH, Associate professor, Ewha Women's University, Change of sexual function after penile rehabilitation following nerve sparing robot assisted laparoscopic radical prostatectomy in the patients with localized prostate cancer
- 2012 Han HH, Investigative research faculty, Yonsei University, Transmesocolic approach for left side laparoscopic pyeloplasty-comparison to laterocolic approach in the initial learning period

2013 Lee DH, Associate Professor, Pusan National University Yangsan Hospital, Busan University. Nerve-sparing robotic radical prostatectomy in high-risk prostate cancer patients: Clinical outcomes for decision-making

FELLOWSHIPS

2005 - 2006 Lee JS, Chief, Mizmedi Hospital, Department of Urology

2006 - 2008 Lee SW, Associate Professor, Hanyang University, Department of Urology

2007 - 2009 Oh CY, Associate Professor, Hallym University, Department of Urology

2009 - 2010 Chung YK, Research Fellow, Harvard Medical School

2009 - 2010 Park KK, Associate Professor, Jeju University, Department of Urology

2010 - 2011 Chung MS, Associate Professor, St. Mary's Catholic University, Department of Urology

2011 - 2013 Lee DH, Associate Professor, Pusan National University Yangsan Hospital, Busan University, Department of Urology

2012 - 2012 Chung HB, Clinical fellow, Hallym University, Department of Urology

2013 - 2015 Koo KC, Associate Professor, Yonsei University, Department of Urology

2014 - 2015 Park SU, Ilsan hospital, Department of Urology

2015 - 2017 Lee KS, Clinical Professor, Yonsei University, Department of Urology

2016 - 2018 Kim DK, Clinical Professor, Soonchunhyang University Seoul Hospital Seoul, Department of Urology

2017 - 2019 Hah YS, Clinical Professor, Catholic University of Daegu, Department of Urology

2019 – Ahn HK, Clinical fellow, Yonsei University, Department of Urology

2020- Yoo JW. Clinical fellow, Yonsei University, Department of Urology

INVITED LECTURES

- Aug 2001 Prostate academy symposium, University program, Jeju, Korea
: BPH on medical Failure
- Nov 2001 Expertise Meeting in Urology(EMU), Jeju, Korea
: Present status of BPH management : therapeutic effects of a-blockers: meta-analysis
- Jun 2002 The 3rd Asan-Samsung Urologic Symposium, Seoul, Korea
: The Role of Retroperitoneal Lymph Node Dissection
- Nov 2002 Expertise Meeting in Urology(EMU), Jeju, Korea
: Emerging concept of LUTS
- Jul 2003 Prostate academy symposium, University program, Sokcho, Korea
: Minimal Invasive Therapy for BPH
- Dec 2003 Expertise Meeting in Urology(EMU), Jeju, Korea
: Maintenance of Medical Treatment in Patients with LUTS ;
Successful long term medical management for men with BPH
- Nov 2004 Expertise Meeting in Urology(EMU), Jeju, Korea
: Consensus for diagnostic work up in LUTS/BPH : Responses from audience
- July 2005 Prostate academy symposium, University program, Seoul, Korea
: Chemoprevention of Prostate Cancer
- Dec 2005 Expertise Meeting in Urology(EMU), Jeju, Korea
: Current issues related to alpha-blocker ;
Role of alpha blocker treatment : BPH/LUTS in real life practice

- May 2007 2nd Prostate Academy, Incheon, Korea
: Current practice of BPH management in Korea : Results of survey
- Jul 2007 The 8th Asan-Samsung Urologic Symposium, Seoul, Korea
: Case Discussion of GU Oncology
- Dec 2007 Expertise Meeting in Urology (EMU), Seoul, Korea
: Management of persistent complains after first line therapy
- Jul 2008 The 9th Asan-Samsung Urologic Symposium, Seoul, Korea
: Update of GU Oncology
- Jul 2008 University program, Busan, Korea
: Paradigm Shift in the Primary Prevention of Prostate Cancer : Reanalysis of the PCPT Data
- Nov 2008 Expertise Meeting in Urology(EMU), Jeju, Korea
: Unsolved problems in male LUTS management : Survey report
- Feb 2009 The 1st Urology Expert Meeting, Seoul, Korea
: Sexuality and the management of BPH with alfuzocin trial
- Aug 2009 ASCOT Speaker Training Meeting, Beijing, China
: Efficacy of Cardura in managing BPH in normotensive and hypertensive men
- Jan 2010 Asia-Pacific Urology Consortium 2010, Nagasaki, Japan
: Diagnosis and Treatment Standard for Treatment-Resistant Patients
- Dec 2010 Expertise Meeting in Urology(EMU), Jeju, Korea
: EMU past 10 years : The Footprints
- Mar 2011 Asia-Pacific Prostate Society 2011, Seoul, Korea
: Consensus Meeting for Asian-Pacific BPH guideline
- Mar 2011 European Association of Urology, EAU-KUA Joint Session, Vienna, Italy
: Intraoperative techniques for improving post-prostatectomy incontinence

- Apr 2011 Philippine Urological Association, Iloilo, Philippines
: Recent Trend of BPH Management in Asia-Pacific Countries
- May 2011 American Urological Association, Korean World Urologic Congress (KWUC), Washington D.C., U.S.A.
: Panel discussion of Clinical Cases of high-risk Prostate Cancer
- Sep 2011 Caring for the Asian prostate cancer patient: Understanding current practice, optimizing treatment outcomes, Taipei, Taiwan
: Current pharmacological management of prostate cancer in Korea
- Nov 2011 Asia-Pacific Urology Consortium(APUC), Sapporo, Japan
: Preventing Progression in Men with LUTS/BPH : Is There an Innovative Management?
- Nov 2011 Asia-Pacific Urology Consortium, Sapporo, Japan
: Preventing progression in men with LUTS/BPH-Is there an innovative management?
- Dec 2011 Expertise Meeting in Urology(EMU), Jeju, Korea
: What Happens in Urologic Clinic?
- Mar 2012 Taiwan Surgery Association Annual Meeting, Taipei, Taiwan
: The evolution of prostate cancer treatment in Korea
- Apr 2012 2nd Asian Pacific Prostate Society(APPS), Seoul, Korea
: Korean Prostate Cancer Database(KCaP)
- Jun 2012 6th Prostate Academy, Busan, Korea
: EAU & AUA update : Urology hot issues
- Jul 2012 Prostate academy symposium, University program
: 1 Year After FDA Announcement Regarding 5αRI
- Aug 2012 11th Asian Congress of Urology, Pattaya, Thailand
: Role of Surgery for High Risk Prostate Cancer

- Oct 2012 Talk concert, Buyeo, Korea
: Big picture of LUTS/BPH : from disease burden to risk
- Dec 2012 Expertise Meeting in Urology(EMU), Jeju, Korea
: New Horizon of Chemotherapeutic agents for HRPC
- Jan 2013 Asia-Pacific Urology Consortium(APUC), Kuala Lumpur, Malaysia
: The Role of Surgery for Locally Advanced Prostate Cancer
- Jan 2013 4th Asan Robotic Surgery Symposium, Seoul, Korea
: My Techniques for the Preservation of Potency and Continence During RARP
- Mar 2013 Update on the Management of Prostate Cancer : Focus on Clinical Practice, Expert meeting,
EAU 2013, Milan, Italy
: Patient with metastatic Prostate Cancer, Still Receiving Hormones
- Mar 2013 European Association of Urology, EAU-KUA Joint Session, Milan, Italy
: Management of Small Renal Masses
- Apr 2013 3rd Asian Pacific Prostate Society(APPS), Melbourne, Australia
: Pathologic Characteristics of Korean Active Surveillance Candidates who Underwent
Radical Prostatectomy
- May 2013 Prostate Cancer Regional Advisory Board Meeting, Ho Chi Minh, Vietnam
: Current Trend in the Management of Prostate Cancer in Korea
- June 2013 Special Course Lecture, Graduate School of Engineering, Yonsei University, Seoul, Korea.
: For an Amalgamation of Medicine and Engineering
- July 2013 STAR 5th Round Meeting, Seoul, Korea
: Complete remission case with TKI therapy
- July 2013 3rd Conference on Nocturia and Nocturnal Enuresis(CNN), Jeju, Korea
: Comparative data from degarelix vs. LHRH agonists

- Sep 2013 Academy for Cancer Education(ACE), Songdo, Korea
: Systemic therapy for CRPC: novel agents and new standards
- Sep 2013 CaPs meeting, New perspectives in prostate cancer, Songdo, Korea
: Prostate cancer database in in Korea
- Sep 2013 NCCN-ACS international conference, Songdo, Korea
- Sep 2013 7th joint meeting of K-CaP and CaPSURE, Songdo, Korea
: Determining the triggers for intervention among men undergoing active surveillance for prostate cancer
- Nov 2013 Radium-223 dichloride Asia Pacific Advisory Board, Bangkok, Thailand
: Current Trends of CRPC management: An Asian Perspective
- Nov 2013 Global Prostate Cancer Scientific Advisory Board on BI836845, Toronto, Canada
: Competitive Landscape and Emerging Standards of Care in CRPC
- Dec 2013 Expertise Meeting in Urology(EMU) 2013, Jeju, Korea
: Prostate Problem: Decision Making Case Scenario
- Dec 2013 Tasquinimod Advisory Board Meeting, Shanghai, China
: PSA screening: Controversies & Recommendations
- Jan 2014 Evolving treatment options in castration-resistant prostate cancer, Seoul, Korea
: Optimal management with abiraterone in the contest of chemotherapy
- Mar 2014 12th KUOS multidisciplinary conference, Seoul, Korea
: Clinical conundrums in the treatment of mCRPC: Bone-targeted radiopharmaceuticals
- Mar 2014 4th congress of asian pacific prostate society(APPS), Okinawa, Japan
: Case & Discussion : Advanced prostate cancer
: Treatment landscape and real life experience of high-risk prostate cancer : A Korean perspective
- Apr 2014 Annual meeting of 102th Japanese urological association, Kobe, Japan

: Introduction of asian pacific prostate society and smart prostate cancer database system

- May 2014 8th Today's urology forum & harnal D seminar, Shanghai, China
: Focus on LUTS/BPH patients : sharing the clinical experience of Harnal-D in Asia
- Aug 2014 Xofigo launching symposium, Seoul, Korea
: Xofigo, new solution for mCRPC treatment : Mechanism of action & ALSYMPCA study
- Aug 2014 Xtandi launching symposium, Seoul, Korea
: How to maximize the benefits of Xtandi
- Sep 2014 Asia pacific prostate society(APPS) symposium, Daejeon, Korea
: National consensus of Korean prostate cancer guideline
- Nov 2014 Expertise Meeting in Urology(EMU), Jeju, Korea
: Sequencing of treatment in CRPC
- Nov 2014 2014 APPS Consensus Meeting with ACU 2014, Kish island, Iran
: Focal therapy for localized prostate cancer : A counterpoint
- Dec 2014 ARAMIS investigator meeting, Seoul, Korea
: Targeting the androgen receptor in nmCRPC
- Dec 2014 Astellas advisory board meeting, Singapore
: Emerging landscape in chemo-naïve CRPC : Unmet needs and emerging landscape
- Jan 2015 6th Asan Robotic Surgery Symposium, Seoul, Korea
: Unedited Expert Videos : My technical tips and tricks for potency preservation during RARP
- Feb 2015 9th Prostate Academy, Busan, Korea
: Prostate cancer and 5aRI
- Mar 2015 NCCN-ACS international conference, New Orleans, USA
- May 2015 4th Academy for Cancer Education(ACE) Asia-Pacific Prostate Cancer Conference, Tokyo, Japan

: Open conversations between panelists and audience on topical issues/FAQs/dilemmas during patient discussions

- Jul 2015 25th Seoul Urological symposium, Bundang, Korea
: Is surgery and appropriate option for oligometastatic prostate cancer?
- Aug 2015 Prostate cancer research symposium, Daegu, Korea
: New paradigm of chemotherapy for hormone-sensitive, advanced prostate cancer
- Oct 2015 2015 APPS Consensus Meeting, Seoul, Korea
: Report on APCCC (Advanced Prostate Cancer Consensus conference) 2015
- Nov 2015 2015 IUA, APSU, FAUA Joint Plenary session, Bali, Indonesia
: NCCN Kidney Cancer Asian Consensus Case presentation : two cases
- Oct 2015 2015 APPS Consensus Meeting, Seoul, Korea
: Report on APCCC (Advanced Prostate Cancer Consensus conference) 2015
- Aug 2016 2016 ACE: Prostate cancer
: Prostate cancer2: castration-resistant
- Sep 2016 2016 APPS The 6th Congress of Asian Pacific Prostate Society
:The Role of Enzalutamide in the Era of Emerging Therapies for CRPC
:Updated Review of Evidence
- Aug 2017 2017 Academy for Cancer Education(ACE), Seoul, Korea
: Treatment sequencing in mCRPC
: Which sequence to provide more benefit with patient for long treatment journey
- Sep 2017 23th Korea-Japan Urological Congress (KJUC), Seoul, Korea
: Prognostic factors in new hormonal agent for mCRPC
- Oct 2017 invitation from Al-Farabi Kazakh National University, Amalty, Kazakhstan
: Robotic Surgery in Prostate Cancer
- Feb 2018 Advanced Prostate Cancer Consensus Conference (APCCC)

Asia Pacific (APAC) Satellite Symposium, Melbourne, Australia
: Management of high risk and locally advanced prostate cancer

Mar 2018 Xtandi Symposium, Seoul, Korea
: The latest updates on Korean landscape in mCRPC status

Sep 2019 2019 The Korean Prostate Society - Asia Pacific Society of Uro-Oncology (KPS-APSU) Joint International Symposium, Seoul, Korea
: Optimal management of male LUTS/BPH – Combination therapy of tamsulosin & dutasteride

PERFORMED AND ONGOING CLINICAL TRIALS

1. Alf-one study (2003.6-2004.6)

Study of the outcome of patients with lower urinary symptoms suggestive of benign prostatic hyperplasia and treated with alfuzosin 10 mg once daily (Xatral XL) for 6 months in Korea

2. Doxazosin study (2004.5 - 2005.5)

A. Doxazosin for Benign Prostatic Hyperplasia: Open-label, Baseline-controlled Study in Korean General Practice
Doxazosin for Benign Prostatic Hyperplasia: Open-label, Baseline-controlled Study in Korean General Practice

B. The Efficacy and Safety of Doxazosin GITS in Patients with Benign Prostatic Hyperplasia

C. The Long-term Efficacy and Safety of Doxazosin GITS in Patients with Benign Prostatic Hyperplasia

3. Zoledronic Acid study (2006 -2012)

A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of I.V. Zometa 4mg on Pain, Skeletal Related Events and Quality of Life in Prostate Cancer Patients with Cancer-Related Bone Lesions

4. CPA (cyproterone acetate) study (2006 - 2007)

Open randomized study of CPA monotherapy comparing intermittent to continuous treatment for prostate cancer

5. CombAT trial (2004 - 2009)

A randomised, double-blind, parallel group study to investigate the efficacy and safety of treatment with dutasteride (0.5mg) and tamsulosin (0.4mg), administered once daily for 4 years, alone and in combination, on the improvement of symptoms and clinical outcome in men with moderate to severe symptomatic ben

gn prostatic hyperplasia

6. Adam Study (2005.12 - 2007.10)
A Randomized, double blind, placebo controlled detrusitol SR "Add-on" to alpha-blocker study in men with persistent overactive bladder symptoms of urinary frequency and urgency with/without urgency incontinence after previous monotherapy with alpha blocker
7. Samba Study (2006.4 - 2008.1)
An open, non-comparative, multicenter study on the sexual function improvement following treatment with alfuzosin (xatral ®XL) in patients with BPH
8. Combo study (2006.4 - 2007)
Initial α -blocker and anti-cholinergic combined treatment in overactive bladder benign prostate obstruction (OAB/BPO) patients, a prospective randomized, multi-center, double-blinded placebo-controlled study.
9. Safety and efficacy of the simultaneous administration of udenafil and an α -blocker in men with erectile dysfunction concomitant with BPH/LUTS (2006.12 - 2008.3)
10. Is obesity a metabolic marker for the development of benign prostatic hyperplasia and lower urinary tract symptoms? (2007.7 - 2008.7)
11. Efficacy and Effects on Quality of Life of Lorelin® Depot Injection in Patients with Prostate Cancer (2007.10 - 2008.11)
12. A Randomized, Double-blind, placebo-controlled Study to Evaluate the Efficacy and Safety of Fesoterodine as an "Add-On" Therapy in Men with Persistent overactive Bladder Symptoms under Monotherapy of Alpha Blocker for Lower Urinary Tract Symptoms (2008.4 - 2009.4)
13. A Phase III Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and safety of Once-daily Orally Administered ZD4054 10mg in Non-metastatic Hormone-resistant Prostate Cancer Patients (2008.3 - 2011)
14. A Phase III, Randomised, Double-blind Study to Assess the Efficacy and Safety of 10mg ZD4054 versus Placebo in Patient with Hormone-resistant Prostate Cancer and Bone metastasis who are pain Free or Mildly symptomatic(2008.3. - 2010.10)
15. Comparative rapid onset efficacy between the two α 1-adrenoreceptor antagonist, doxazosin and tamsulosin, in patients with lower urinary tract symptoms from benign prostatic hyperplasia (2008.5 - 2010)

16. Comparison of clinical efficacy in medical treatment of BPH related to the body mass index (COMBI) trial (2008.8 -2010)
17. Minirin "add-on" effect in men with persistent nocturia after previous monotherapy with alpha blocker (2009.4 - 2011)
18. A prospective, open-label, observational multi-center study for the identification of predictive factors for the solifenacin treatment in men with overactive bladder symptoms after tamsulosin monotherapy for 4 weeks and evaluation of efficacy and persistency of add on solifenacin in men with residual overactive bladder symptoms after previous monotherapy with tamsulosin. (2009.1 - 2010)
19. A Randomized, Double-blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer (2009 - Present)
20. The Clinical Study of Leuprolide Acetate 11.25 mg for Evaluation of Efficacy and Safety in Patients with Prostatic Cancer (2009 - 2011)
21. A randomized, double-blind, parallel group study to investigate the efficacy and safety of treatment with finasteride (5mg), tamsulosin (0.2mg), GL 2701, in men with lower urinary tract symptomatic benign prostatic hyperplasia (2009 - 2011)
22. An Open-label, Multi-Centre Trial, Bridging Efficacy and Safety of Degarelix One-Month Dosing Regimen in Korean Patients with Prostate Cancer Requiring Androgen Ablation Therapy (reference group:CS21 Trial 240/80 mg non-Asian Patients) (2010 - 2011.12)
23. An Open-label, Multi-Centre, Extension Trial, Evaluating the Long-Term Safety and Tolerability of degarelix One-Month Dosing Regimen in Korea Patients Requiring Androgen Ablation Therapy (2010.12 - 2012)
24. Clinical efficacy and safety of Mvix (mirodenafil) 50mg daily treatment on unsatisfactory improvement of LUTS and ED after alpha blocker treatment in BPH patients (2011.1 - 2011.9)
25. A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination with Custirsen(OGX-011) in Men with Metastatic Castrate Resistant Prostate Cancer (2011 - 2013)
26. A Phase 3, Randomized, Double -Blind, Multicenter Trial Comparing Orteronel(TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-RESISTANT Prostate Cancer That H

as Progressed During or Following Docetaxel-based Therapy (2011 - 2014)

27. A Phase 2 Open Label Study of Abiraterone Acetate and Prednisolone in Patients with Advanced Prostate cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy (2011 - Present)
28. A Phase 1 clinical trial to evaluate the safety and pharmacokinetics of EO9 (Apaziquone) intravesical instillation of patients with non-muscle invasive bladder cancer (2011.5 - 2012.4)
29. A Phase 3, Randomized, Double –Blind, Placebo-Controlled Study of Tasquinimod in Men with Metastatic Castrate –Resistant Prostate Cancer (2012.2 - present)
30. A Multinational Phase 3, Randomized ,Double–Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy –Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy (2011.12 – Present)
31. Randomized ,placebo-controlled ,double blinded study of single immediate instillation of EO9 after TURBT in patients with NMIBC. (2012.2 - 2014)
32. PROSPER: A multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients with NMCRPC((2014.1 – present)
33. A Phase 3, randomized, double-blind, placebo-controlled study of Tasquinimod in Asian chemo-naïve patients with Metastatic Castrate-resistant Prostate cancer(2014.03– 2015.09)
34. A Randomized, Double–Blind, Parallel group study to compare the efficacy and safety of combination treatment with dutasteride and tamsulosin in men with moderate to severe BPH. (2014.04 – present)
35. A Randomized, Double–Blind, Placebo-and Active-controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron in the Treatment of Overactive Bladder. (2014.5 – present)
35. A multicenter, single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with mCRPC treated with Enzalutamide Who are at Potential Increased Risk of Seizure , Phase 4 (2014.08– present)
36. A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase3 Study of ARN-509 in Men with Non-

Metastatic(M0)CRPC (2014. 10-present)

37. . A tree arm randomized, Open-label Phase 2 study of radium-223 dichloride 50 kBq/kg versus 80 kBq/kg and versus 50 kBq/kg in an extended dosing schedule in subjects with castration-resistant prostate cancer metastatic to the bone (2014.12-present)

38. A multinational, Randomized, Double-Blind, Placebo-controlled, Phase 3 Efficacy and Safety study of ODM-201 in men with high-Risk non-metastatic CRPC(2015.01~ present)

GCP EDUCATION

2003. GSK

2008. Pfizer

2008. Astrazeneca

2009. BMS

2010. CITI

2011.9 NIH

2012.11 CITI

2015.02 CITI

2015.03 NIH

I hereby, certify the above statement to be true and correct in every detail.

16 October, 2019

Byung Ha CHUNG, M.D., Ph.D.



<Attached separate sheets - Published articles>

1. **Chung BH**, Park HS, Kim CI, Lee JM, Jin SY, Park CI. Nonfunctioning adrenocortical carcinoma : a case report. Korean J Urol. 1985;26:513-516.
2. **Chung BH**, Mah SY. Acute urinary retention in the female. Korean J Urol. 1985;26:691-695.
3. Yoon JH, Ahn SK, Lee YB, **Chung BH**, Yang SC : Report of a case of renal actinomycosis. Kor J Path. 1986;20:383-387.
4. **Chung BH**, Mah SY, Choi SK. A case of ectopic ureteral orifices in unilateral duplicated ureter. Korean J Urol. 1986;27:309-311.
5. Lee MS, **Chung BH** . Early experience of percutaneous nephrolithotomy. Korean J Urol. 1986;27:417-423.
6. **Chung BH**, Choi SK, Chung WH. A case of adrenal ganglioneuroma. Korean J Urol. 1986;27:561-563.
7. Choi HK, **Chung BH**. Erection penogram with papaverine and 99m Tc-HSA. J Urol. 1987;137:184A.
8. Choi SK, **Chung BH**, Lee MK. A clinicopathological study of unilateral absent testis in 23 boys. Korean J Urol. 1987;28:259-262.
9. Lee MS, Yang SC, Choi YD, **Chung BH**. Endoscopic surgery for ureteropelvic junction obstruction. Korean J Urol. 1988;29:83-88.
10. **Chung BH**, Chung KH. Computerization of urologic records: for users of Macintosh typed personal computer. Korean J Urol. 1991;32:1018-1023.
11. Choi JH, Kim JT, **Chung BH**, Park JY. Transrectal ultrasonography: evaluation of bladder wall invasion in cervical cancer. Korean J Urol. 1992;33:812-815.
12. **Chung BH**, Chung KH, Lee JH, Kim JH, Choi JY. Hydronephrosis secondary to congenital pelvic arteriovenous malformation: a case report. J Urol. 1992;148:1877-1879.
13. Kim JT, **Chung BH**, Chung KH. Hydronephrotic atrophy after partial ureteral obstruction: experimental model and natural history. Korean J Urol 1993;34:191-197.
14. Chung KH, Kim JT, **Chung BH**. Transrectal ultrasonography in lower urinary tract for women without stress urinary incontinence. Korean J Urol. 1993;34:207-211.
15. Choi JH, **Chung BH**, Chung KH. Dissolution of uric acid calculi with alkali fluid irrigation through percutaneous nephrostomy tube. Korean J Urol. 1993;34:341-344.
16. Kang JS, Kim TH, Park KB, **Chung BH**, Youn JI. Enoxacin photosensitivity. Photodermatol Photoimmunol Photomed. 1993;9:159-161.
17. **Chung BH**, Chang KC. Does nitric oxide mediate the relaxation of rat detrusor. The Proceedings of ICS 23rd Annual Meetings 1993;101
18. **Chung BH**, Chang KC. Further evidence that NO- and NO2-carrying molecules potentiate photorelaxation. Gen Pharmacol. 1994;25:893-898.
19. **Chung BH**, KC Chang, SK Choi. Effect of Nitric oxide generated by photolysis on the rat detrusor. Korean J Urol. 1994;35:1054-1064.
20. Hwa JS, Choi BS, Lee H, **Chung BH**. Clitoral involvement by neurofibromatosis. Korean J Urol. 1994;35:1277-1279
21. **Chung BH**, Chang KC. Photo-induced Adequate Nitric Oxide(PIANO)-mediated Relaxation in Isolated Rabbit Corpus Cavernosum. Gen Pharmacol. 1994;25:893-898.
22. Lee DH, Hong SJ, **Chung BH**. The Gleason and Change of Serum PSA after Maximum Androgen Blocking in Patients with Metastatic Prostate Cancer. Korean J Urol. 1995;36:815-818.
23. **Chung BH**, Hong SJ, Lee SE, Lee DH. Serum PSA concentration, Prostate Specific Antigen Density with Aging. Korean J Urol. 1996;37:257-262.

24. Park DW, Hong SJ, **Chung BH**, Kim MJ. Color Doppler Image in the Prostatitis and Benign Prostatic Hyperplasia. Korean J Urol. 1996;37:516-520.
25. **Chung BH**, Hong SJ, Sung DH, Mah SY, Song JM, Chung WS, Shim BS, Choi HR, Kwon SW. Clinical Significance of Measuring Free form of Prostate-Specific Antigen. Korean J Urol. 1996;37:510-515
26. Lee DH, Hong SJ, **Chung BH**, Park DW. Early Experience of Combination Therapy with Chemo-Immuno-Hormonal Agents in Advanced Renal Cell Carcinoma. Korean J Urol. 1996;37:639-645.
27. Lee DH, Hong SJ, **Chung BH**. Early Experience of Strontium-89 Therapy for Pain Palliation in the Patients with Symptomatic Metastatic Prostate Cancer. Korean J Urol. 1996;37:974-978.
28. **Chung BH**, Lee DH, Hong SJ. The Relationship of Cellular Composition of Benign Prostatic Hyperplasia and Prostate-Specific Antigen (PSA) Levels. Korean J Urol. 1996;37:1093-1096
29. Hong SJ, Park DS, **Chung BH**, Song YS, Lee DH. Histo-immunological Effect of Exogenous Testosterone on the Experimentally Induced Autoimmune Mouse Prostatitis. Korean J Urol. 1996;37:1193-1200.
30. Hong SJ, **Chung BH**, Seo JW, Chung BC, Park DS, Lee DH. Urinary Polyamine Profiles and Benign Prostatic Hyperplasia. Korean J Urol. 1996;37:1398-1403.
31. Hong SJ, Lee T, Park YS, Lee KO, **Chung BH**, Lee SH. A PCR-RFLP Method for the Detection of Activated H-ras Oncogene with a Point Mutation at Codon 12 and 61. Yonsei Med J. 1996;37:371-379.
32. **Chung BH**, Choi SK, Chang KC. Effects of Nitric Oxide on Detrusor Relaxation. J Urol. 1996;155:2090-2093.
33. Choi HR, Chung WS, Shim BS, Kwon SW, Hong SJ, **Chung BH**, Sung DH, Lee MS, Song JM. Translation Validity and Reliability of I-PSS Korean Version. Korean J Urol. 1996;37:659-665.
34. Lee DH, **Chung BH**, Hong SJ. The Effect of Medroxyprogesterone Acetate on Cytotoxicity of Vinblastine in Renal Cell Carcinoma Cell Lines. Korean J Urol. 1997;38:1-6.
35. Yang SC, Lee DH, Hong SJ, **Chung BH**, Kim IY. Telomerase Activity: A Potential Marker of Bladder Transitional Cell Carcinoma in Bladder Washes. Yonsei Med J. 1997;38:155-159.
36. Hong SJ, **Chung BH**, Kim JH. Prostate Surgery. Medical Progress 1997:5-8.
37. Choi HR, Chung WS, Shim BS, Kwon SW, Hong SJ, **Chung BH**, Lee MS, Choi HK, Song JM. Prevalence and Characteristics of Prostatism in Korea: Application of I-PSS. Korean J Urol. 1997;38:1067-1074.
38. Lee MS, Yang SC, Hong SJ, **Chung BH**, Chung YH. Telomerase Activity in Transitional Cell Carcinoma of Bladder. Korean J Urol. 1997;38:1147-1150.
39. Hong SJ, **Chung BH**, Lee DH. Bladder preservation in muscle invasive bladder cancer. British J Urol. 1997;80:56.
40. Lee DH, Yang SC, Hong SJ, **Chung BH**. Clinical significance of telomerase activity in bladder wash specimens. British J Urol. 1997;80:73.
41. Hong SJ, Lee DH, **Chung BH**. Chemo-Immuno-Hormonal combination therapy for metastatic renal cell carcinoma. British J Urol. 1997;80:128.
42. Hong SJ, **Chung BH**, Lee DH. Transurethral radiofrequency thermotherapy for symptomatic patients with benign prostatic hyperplasia(BPH): Two year follow-up. British J Urol. 1997;80:190.
43. **Chung BH**, Hong SJ, Lee MS, The Korean Doxazosin Study Group. Doxazosin in the treatment of benign prostatic hyperplasia(BPH): An open, baseline-controlled study in Korean general urology practice. British J Urol. 1997;80:219.
44. **Chung BH**, Hong SJ, Lee DH, Mah SY. Abnormal liver function with the use of flutamide in patients with advanced prostate

cancer in Korea. *British J Urol.* 1997;80:283.

45. **Chung BH**, Hong SJ, Lee DH, Kang SJ, Mah SY. Incidence of Flutamide-induced Liver Toxicity in Patients with Prostate Cancer in Korea. *Korean J Urol.* 1998;39:41-44.
46. **Chung BH**, Lee DH, Hong SJ. Retroviral Vector-mediated Interleukin-2 Gene Transfer into Human Renal Cell Carcinoma Cell Line. *Korean J Urol.* 1998;39:418-422.
47. Song HW, **Chung BH**, Hong SJ. Clinical Experience of Nonseminomatous Germ Cell Testicular Tumor: Risk Factors and Survival Rate. *Korean J Urol.* 1999;40:453-457.
48. **Chung BH**, Chung HJ, Hong SJ, Lee MS, The Korean Doxazosin Study Group. Doxazosin in the Symptomatic Treatment of Benign Prostatic Hyperplasia. *Korean J Urol.* 1999;40:607-612.
49. Hong SJ, Chung HJ, Rha KH, Huh YS, **Chung BH**, Jung SH. Relationship between Lower Urinary Tract Symptom and Hypertension: Coprevalence Rate and Symptom Severity. *Korean J Urol.* 1999;40:729-733.
50. Lee MS, **Chung BH**, Chung HJ, Lee SE, Sung KM, Choi MJ, Cho YH, Han JH. The Experimental Effect of High Intensity Focused Ultrasound(HIFU) being Developed in Korea. *Korean J Urol.* 1999;40:1003-1011
51. **Chung BH**, Chung HJ, Hong SJ. Long-Term Efficacy and Safety of Terazosin in the Symptomatic Treatment of Benign Prostatic Hyperplasia. *J Korean Andrological Society* 1999;17:45-50.
52. **Chung BH**, Kim JH, Hong CH, Yang SC, Lee MS. Comparison of single and multiple sessions of percutaneous sclerotherapy for simple renal cyst. *BJU Int.* 2000;85:626-627.
53. Byun YJ, **Chung BH**, Kwon KW. Inflammatory Pseudotumor of Urinary Bladder. *Yonsei Med J.* 2000;41:273-275.
54. **Chung BH**, Mitchell SH, Zhang JS, Young CYF. Effects of docosahexaenoic acid and eicosapentaenoic acid on androgen-mediated cell growth and gene expression in LNCaP prostate cancer cells. *Carcinogenesis* 2001;22:1201-1206.
55. **Chung BH**, Chang SY, Kim SI, Choi HS. Successfully treated renal fungal ball with continuous irrigation of fluconazole. *J Urol.* 2001;166:1835-1836.
56. Hong SJ, Kim SI, Kwon SM, Kim YS, **Chung BH**. Association of cyclooxygenase-2 expression with prognosis of stage t1 grade 3 bladder cancer. *Urology* 2002;60:816-821.
57. **Chung BH**, Ko WJ, Kim SI, Hong SJ. Identification of baseline clinical factors that predict maintenance for medical treatment of BPH. *Eur Urol.* 2003;44:94-100.
58. Son JI, Chung JP, Paek SS, Lee JI, Kim JH, Moon BS, Lee KS, Lee SI, Moon YM, Park CI, Kim HR, **Chung BH**. A case of granulomatous hepatitis developed after intravesical BCG instillation for bladder cancer. *Korean J Gastroenterology* 2002;39:375-378.
59. Lee SJ, Lee CH, Kim SW, Cho YH, Shin WS, Lee SE, Kim CS, Hong SJ, **Chung BH**, Yoon MS. Comparative study on the incidence of urinary tract infection between nitrofurazone-coated urinary catheter and silicone catheter. *Korean J Infect.* 2002;34:184-190.
60. Cha KB, **Chung BH**, Hong SJ. Clinical manifestation of tumor recurrence and progression after transurethral resection and BCG intravesical instillation in patients with T1G3 bladder cancer. *Korean J Urol.* 2002;43:490-495.
61. Bai SW, **Chung BH**, Chung BC, Kim SK, Park KH. Relationship between Urinary Endogenous Steroid Metabolites and Lower Urinary Tract Function in Postmenopausal Women. *Yonsei Med J.* 2003;44:279-287.
62. **Chung BH**, Kim JW, Lee JS, Hong SJ. Can 12 core prostate biopsy increase the detection of prostate cancer over 6 core? *Eur Urol.* 2003;1:426.

63. Hong SJ, Ko WJ, Kim SI, **Chung BH**. Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia: an observational cohort study. *Eur Urol.* 2003;44:94-99
64. Lee DY, **Chung BH**, Hong SJ. Bladder preservation strategies for treatment of muscle-invasive bladder cancer: Experience of 7-year follow up. *Korean J Urol.* 2003;44:391-396.
65. Kim DS, **Chung BH**. Translation validity and reliability of the Korean version of the DAN-PSS. *Korean J Urol.* 2003;44:871-875.
66. **Chung BH**, Kim JW, Lee JS, Hong SJ. Proper cut-off value of free to total PSA ratio for detection of prostate cancer in Korean men. *Yonsei Med J.* 2004;45:873-878.
67. DH Kim, SI Kim, YS Kim, CI Kim, HS Kim, DH Seong, SC Yang, SH Cheon, **Chung BH**, IR Cho, JS Cho, YD Choi, Severance Urologic Oncology Group. Probability of prostate cancer on biopsy according to serum PSA level in Korean men: Is there any racial difference? *Eur Urol.* 2004:132
68. **Chung BH**, Han KS, Kim JW, Lee HY, Hong SJ. Changing patterns in the management of benign prostatic hyperplasia. *Eur Urol.* 2004;3:232.
69. Cho KS, Hong SJ, **Chung BH**. The Impact of Positive Surgical Margins on Biochemical Recurrence after Radical Retropubic Prostatectomy. *Korean J Urol.* 2004;45:416-422.
70. Park EK, Hong SJ, **Chung BH**. Influences of Neoadjuvant Androgen Ablation before Radical Prostatectomy on Positive Surgical Margin and Biochemical Recurrence Rate. *Korean J Urol.* 2004;45:518-523.
71. **Chung BH**, Park EK, Hong SJ. The Efficacy and Safety of Doxazosin GITS in Patients with Benign Prostatic Hyperplasia. *Korean J Urol.* 2004;45:667-673.
72. Im YJ, Hong SJ, **Chung BH**. Clinical Application of Free to Total PSA Ratio in Detection of Prostate Cancer in Korean Men : Lower Cut-off Value. *Korean J Urol.* 2004;45:753-757.
73. Kim JW, Lee HY, Hong SJ, **Chung BH**. Can a 12 Core Prostate Biopsy Increase the Detection Rate of Prostate Cancer versus 6 Core?: A Prospective Randomized Study in Korea. *Yonsei Med J.* 2004;45:671-675.
74. Lee SJ, Kim SW, Cho YH, Shin WS, Lee SE, Kim CS, Hong SJ, **Chung BH**, Kim JJ, Yoon MS. A comparative multicentre study on the incidence of catheter-associated urinary tract infection between nitrofurazone-coated and silicone catheters. *Int. J Antimicrobial Agents* 2004;24:65-69.
75. Im YJ, Kim JW, Hong SJ, **Chung BH**. Proper Cut-off Value of Free to Total PSA Ratio for Detection of Prostate Cancer in Korean Men. *Yonsei Med J.* 2004;45:873-878.
76. Park JK, Kim CS, Park CH, Lee JG, **Chung BH**, Hong SJ. Effects of Alpha 1 Adrenoreceptor Antagonist Tamsulosin on Sexual Function in Patients with Benign Prostatic Hyperplasia. *Kor J Androl.* 2004;22:146-150.
77. **Chung BH**, Yang KM, Hong SJ. Meta-analysis of Alpha Receptor Antagonist for Benign Prostatic Hyperplasia from Papers were Published in Korea. *Korean J Urol.* 2005;46:252-258.
78. **Chung BH**, Hong SJ, Lee MS. Doxazosin for benign prostatic hyperplasia: open-label, baseline-controlled study in Korean general practice. *Int J Urol.* 2005;12:159-165.
79. Lee DH, Yang WJ, **Chung BH**, Kim SI, Kim SJ, Kim YS, Kim HS, Seong DH, Song JM, Yang SC, Cheon SH, Cho IR, Cho JS, Choi YD, Hong SJ, Kim CI. A Multicenter Study of the Detection Rate for Prostate Cancer according to the Serum Prostate-Specific Antigen Level in Korean Men. *Korean J Urol.* 2005;46:433-437.
80. **Chung BH**, Kim YS, Hong SJ. 12-MONTH Follow-up Study to Evaluate the Efficacy and Safety of Doxazosin GITS in Patients with Benign Prostatic Hyperplasia. *Korean J Urol.* 2005;46:451-457.

81. Han KS, Hong SJ, **Chung BH**. Changing Trends in the Management of Benign Prostatic Hyperplasia during Recent 5 Years. Korean J Urol. 2005;46:458-462.
82. **Chung BH**. Nutritional Treatment of Prostate Cancer: A Scientific Approach. KAM 2005;2:263-268.
83. Hong SJ, Lee JS, **Chung BH**, Kwon SM, Kim SI. Prognostic Value of Cyclooxygenase-2 and p53 Expression in Stage T1 Grade III Bladder Cancer. Korean J Urol. 2005;46:785-791.
84. Cho JS, Kim CI, Seong DH, Kim HS, Kim YS, Kim SJ, Cho IR, Cheon SH, Lee DH, Yang WJ, Choi YD, Hong SJ, Ju YS, Song YS, Kim SI, **Chung BH**. Relationship between Serum Prostate-Specific Antigen and Prostate Volume in Men with Benign Prostatic hyperplasia from Multicenter Study. Korean J Urol. 2005;46:792-798.
85. Lee JS, **Chung BH**, Seo JT. The Effect of Ureaplasma urealyticum and Mycoplasma hominis in Semen on Sperm Analysis Parameters in Infertile Men. Korean J Urol. 2005;46:1028-1033.
86. Park EK, Yang WJ, Choi YD, **Chung BH**, Rha KH, Yang SC, Mah SY, Hong SJ. The Significance of Repeat prostate Biopsy for the Detection of Prostate Cancer. Korean J Urol. 2005;46:1268-1271.
87. Oh CY, Lee JS, **Chung BH**. A validation and reliability study for the Korean version of the male sexual health questionnaire. Korean J Urol. 2005;46:1308-1326.
88. **Chung BH**, Hong SJ, Korean Doxazosin Gastrointestinal Therapeutic System Study Group. Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension. BJU Int. 2006;97:90-95.
89. **Chung BH**, Hong SJ. Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension. BJU Int. 2006;97:90-95.
90. Cho JS, **Chung BH**, Kim SJ, Kim YS, Kim CI, Kim HS, Seong DH, Song YS, Yang WJ, Cheon SH, Cho IR, Choi YD, Hong SJ. Relationship between prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study. BJU Int. 2006;97:742-746.
91. **Chung BH**, Hong SJ. Long-term follow-up study to evaluate the efficacy and safety of doxazosin GITS in patients with BPH with and without concomitant hypertension. BJU Int. 2006;97:90-95.
92. **Chung BH**, Lee HY, Lee JS, Young CY. Perillyl alcohol inhibits the expression and function of the androgen receptor in human prostate cancer cells. Cancer Lett. 2006;236:222-228.
93. **Chung BH**, Hong SJ, Cho JS, Seong DH. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia : a multicenter study. BJU int. 2006;97:742-746.
94. Joung JY, Park JK, Park CH, Lee JG, **Chung BH**, Hong SJ, Kim CS. The Role of Alpha 1(A) Adrenoceptor Antagonist Tamsulosin for the Treatment of Patients with Benign Prostatic Hyperplasia: The Effect on Lower Urinary Tract Symptoms and Nocturia. Korean J Urol. 2006;47:1-6.
95. Seong DH, Cho JS, Hong SJ, **Chung BH**, Choi YD, Kim SJ, Lee DH, Cho IR, Kim YS, Kim CI, Ki, SI, Song JM, Cheon SH, Kim HS. The Influence of Age and Prostate Volume on the Cancer Detection Rate in Korean Men with PSA Levels of 4.0 to 10.0ng/ml: a Multicenter, Retrospective Study. Korean J Urol. 2006;47:353-357.
96. Cho JS, Lee KS, Kim BW, Kim SW, Kim CS, Noh CH, Rhew HY, Park KS, Park DS, Park JS, Park JK, Seo IY, Oh TH, Lee SE, **Chung BH**, Jung SI, Chung JI, Jung HC, Cho IR, Kim CI. The Influence of Chlormadinone Acetate on the Total and Free Serum Prostate Specific Antigen Levels in Men with Benign Prostatic Hyperplasia. Korean J Urol. 2006;47:368-371.
97. Soh BH, Lee JS, **Chung BH**. The Changing Pattern of Serum Prostate Specific Antigen in Patients with Benign Prostatic

- Hyperplasia after Combined Treatment with Finasteride and α -blockers: the 3 Year Follow-up Data. Korean J Urol. 2006;47:372-376.
98. Yang KM, Han KS, Yim YJ, Lee JS, Hong SJ, **Chung BH**. Internet Based Multi-institute Prostate Research System: Pilot Experience with a Convenient, Secure and Efficient System. Korean J Urol. 2006;47:387-391.
99. Kim YS, Lee JS, **Chung BH**. Early Experience on the Effects of Sildenafil Citrate for Treating Erectile Dysfunction after Radical Retropubic Prostatectomy. Korean J Urol. 2006;7:392-396.
100. Hong SJ, **Chung BH**, Kim JS, Lee MJ, Yoon S, Oh HY, Lee EJ, Kim HG, Buxian S. The Effects of GAC on the Biochemical Profiles and Quality of Life of Metastatic Prostate Cancer Patients. Korean J Urol. 2006;7:467-474.
101. Kim SS, Oh CY, Kim HJ, Lee SH, Lee JS, **Chung BH**. Frequency-Double Double-Pulse Nd:Yag(Freddy) Laser for the Treatment of Ureteral Stone: Initial Experience. Korean J Urol. 2006;7:502-506.
102. Yang WJ, Lee DH, **Chung BH**, Cho JS, Choi YD, Kim SJ, Cho IR, Kim HS, Kim CI, Hong SJ, Members of the Severance Urologic Oncology Group. Detection rate of prostate cancer on biopsy according to serum prostate-specific antigen in Korean men: A multicenter study. Urology. 2006;67:333-336.
103. Yang WJ, Cho KS, Rha KH, Lee HY, **Chung BH**, Hong SJ, Yang SC, Choi YD. Long-term effects of ileal conduit urinary diversion on upper urinary tract in bladder cancer. Urology 2006;68:324-327.
104. Kim CS, Park SC, Lee SB, Lee JM, Chung H, Chung MK, Yoon DK, Cheon J, Kim WJ, **Chung BH**, Hong SJ, Song JM, Chang SG, Choi HY, Rim JS, Cho YH, Moon KH, Kim BW. The Use of Complementary and Alternative Medicine in Patients with a Urological Malignancy. Korean J Urol 2006;47:620-624.
105. Song CR, Ro JY, Lee MS, Hong SJ, **Chung BH**. Prostate cancer in Korean men exhibits poor differentiation and is adversely related to prognosis after radical prostatectomy. Urology 2006;68:820-824.
106. Hong SJ, Cho KS, Cho HY, Ahn H, Kim CS, **Chung BH**. A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer. Yonsei Med J. 2007;48:1001-1018.
107. Song CR, Kang TJ, Lee MS, Ro JY, Lee SE, Lee FS, Choi HY, Han DH, Hong SJ, **Chung BH**, Kim CS, Ahn HJ. Clinicopathological Characteristics of Prostate Cancer in Korean Men and Nomograms for the Prediction of the Pathological Stage of the Clinically Localized Prostate Cancer: A Multi-institutional Update. Korean J Urol. 2007;48:125-130.
108. Lee JS, **Chung BH**. Transrectal Ultrasound versus Magnetic Resonance Imaging in the Estimation of Prostate Volume as Compared with Radical Prostatectomy Specimens. Urol Int. 2007;78:323-327.
109. **Chung BH**. Medical Management for Benign Prostatic Hyperplasia. Korean J Urol. 2007;48:233-243.
110. Oh HY, Lee EJ, Yoon S, **Chung BH**, Cho KS, Hong SJ. Cholesterol Level of Lipid Raft Microdomains Regulates Apoptotic Cell Death in Prostate Cancer Cells Through EGFR-Mediated Akt and ERK Signal Transduction. Prostate. 2007;67:1061-1069.
111. Hong SJ, Cho KS, Choi HY, Ahn HJ, Kim CS, **Chung BH**. A Prospective, Multicenter, Open-label Trial of Zoledronic Acid in Patients with Hormone Refractory Prostate Cancer. Yonsei Med J 2007;48:1001-1008.
112. Cho JS, Kim SI, Kim SJ, Kim YS, Kim CI, Kim HS, Seoun DH, Song YS, Lee DH, Yang WJ, CheonSH, Cho KS, Cho IR, **Chung BH**, Choi YD, Im H, Hong SJ. Estimated Prostate Cancer Prevalence in Korean Men with Serum Prostate-specific Antigen 2.5-9.9ng/ml. Korean J Urol oncol. 2007;5:144-147.
113. Choi HM, Cho KS, Cho SY, Choi YD, **Chung BH**, Hong SJ. The Patterns and Risk Factors for Subsequent Bladder Recurrence in Patients with Transitional Cell Carcinoma of the Upper Urinary Tract : A Long Term Follow-up Study. Korean J Urol. 2008;49:294-299.

114. Cho JS, Kim SI, Kim SJ, Kim YS, Kim CI, Kim HS, Seong DH, Song YS, Lee DH, Yang WJ, CheonSH, Cho KS, Cho IR, **Chung BH**, Choi YD, Im H, Hong SJ. Lowering Prostate-specific Antigen Threshold for Prostate Biopsy in Korean Men: Impact on the Number Needing Biopsy. *Korean J Urol*. 2008;49:118-121.
115. Cho KS, Choi YD, Kim SJ, Kim CI, **Chung BH**, Seong DH, Lee DH, Seong J, Lee DH, Cho JS, Cho IR, Hong SJ. A Comprehensive Prognostic Stratification for Patients with Metastatic Renal Clear Cell Carcinoma. *Yonsei Med J*. 2008;49:451-458.
116. Cho KS, Cho NH, Park SY, Cho SY, Choi YD, **Chung BH**, Yang SC, Hong SJ. Prognostic Impact of Peripelvic Fat Invasion in pT3 Renal Pelvic Transitional Cell Carcinoma. *J Korean Med Sci*. 2008;23:434-438.
117. Kim SI, Choi YD, Kim SJ, **Chung BH**, Lee DH, Cheon SH, Cho JS, Song YS, Kim YS, Cho IR, Lee DH, Song KH, Kim HS, Lee JS, Yang WJ, Hong SJ. A Multi-institutional study in Histopathological Characteristics of Surgically Treated Renal Tumors: the Importance of Tumor Size. *Yonsei Med J*. 2008;49:639-646.
118. **Chung BH**, CG Roehrborn, P Siami, K Major-Walker, BB Morrill, TH Wilson and F Montorsi, on behalf of the CombAT Study Group. Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH. *Prostate Cancer and Prostatic Dis*. 2009;12:152-159.
119. Park SY, Ham WS, Jeong WJ, Kim WT, Choi YD, **Chung BH**, Hong SJ, Rha KH, Application of Robotic Surgery to Urologic Malignancy: A Single Center Experience. *Korean J Urol Oncol* 2008;6:133-137.
120. **Chung BH**, Lee JY, Kim CI, Kim CS, Oh CY, Lee SW, Lee JS, Yoo SJ. Sexuality and the management of BPH with alfuzosin(SAMBA) Trial. *Int J Impot Res*. 2009;21:68-73
121. **Chung BH**, Lee JY, Lee SH, Yoo SJ, Lee SW, Oh CY Safety and efficacy of the simultaneous administration of udenafil and an α -blocker in men with erectile dysfunction concomitant with BPH/LUTS. *Int J Impot Res*. 2009;21:122-128.
122. Cho KS, Choi HM, Koo KC, Park SJ, Rha KH, Choi YD, **Chung BH**, Cho NH, Yang SC, Hong SJ. Clinical Significance of Lymph Node Dissection in Patients with Muscle-Invasive Upper Urinary Tract Transitional Cell Carcinoma Treated with Nephroureterectomy. *J Korean Med Sci*. 2009;24:674-678.
123. Choi HM, Choi HK, Kim CE, **Chung BH**. Comparison of Voiding Parameters According to the Subtypes of SS-Penogram in Patients with Both Erectile Dysfunction and Lower Urinary Symptoms. *Korean J Androl*. 2009;27:89-95.
124. Lee SH, Kim JC, Lee JY, Kim JH, Oh CY, Lee SW, Yoo SJ, **Chung BH**. Effects of components of metabolic syndrome on sexual function in Korean BPH/LUTS patients. *J Sex Med*. 2009;6:2292-2298
125. Lee SW, Lee SH, Oh CY, **Chung BH**, Efficacy and Safety of Alfuzosin 10 mg Once Daily in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A 6-Months Study in Real Life Practice. *Korean J Urol*. 2009;50:333-339.
126. Lee SH, Oh CY, **Chung BH**. Open label studies sufficiently demonstrate efficacy in improving sexual function. *Int J Impot Res*. 2009;21:265-266.
127. Park SY, Jeong W, Choi YD, **Chung BH**, Hong SJ, Rha KH. Yonsei experience in robotic urologic surgery-application in various urological procedures. *Yonsei Med J*. 2008;49:897-900.
128. Lee SH, Kim JC, Lee JY, Kim JH, Oh CY, Lee SW, Yoo SJ, **Chung BH**. Effects of obesity on lower urinary tract symptoms in Korea BPH patients. *Asian J Androl* 2009;11:663-668.
129. Yu JS, Chung JJ, Hong SW, **Chung BH**, Kim JH, Kim KW. Prostate Cancer: Added Value of Subtraction Dynamic Imaging in 3T Magnetic Resonance Imaging with a Phased-array Body Coil. *Yonsei Med J*. 2008;49:765-774.

130. Kwon MS, Oh CY, Yoo CH, Kim SI, Kim SJ, Kim DJ, Kim YS, Kim CI, Kim HS, Seong DH, Song KH, Song YS, Yang WJ, Lee DH, Cheon SH, Cho IR, **Chung BH**, Choi YD, Hong SJ, Im H, Cho JS. Prostate-specific Antigen Test Interval according to Baseline Prostate-Specific Antigen and Age. *Korean J Urol*. 2009;50:1059-1065.
131. Kim DS, Byun SS, Lee SE, Lee E, Choi HY, **Chung BH**, Choi YD, Ahn HJ, Hwang TK, Lee KH, Kim WJ, Chung MK, Cheon J, Kim HJ, Jung TY, Kwon TG. The Features and Prognosis of Korean Who Underwent Radical Prostatectomy in Prostate Cancer. *Korean J Urol Oncol*. 2010;8:40-46.
132. Chang HS, Park CH, Kim DK, Park JK, Hong SJ, **Chung BH**, Lee JG, Kim CS, Lee KS, Kim JC. Assessment of Patient-Reported Outcome of Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic hyperplasia and Treated With Tamsulosin HCl in Korea. *Urology* 2010;75:1156-1161.
133. Lee SH, Kim DK, Kim JC, Lee KS, Lee JG, Park CH, Hong SJ, Kim CS, Park JK, **Chung BH**, The urologist's view of male overactive bladder: discrepancy between reality and belief in practical setting. *Yonsei Med J*. 2010;51:432-437.
134. Song YS, Cho JS, Cho KS, Doo SH, **Chung BH**, Kim SJ, Yang WJ, Song KH, Kim CI, Hong SJ. Efficacy transitional cell carcinoma of the bladder and upper urinary tract. *Urol Int*. 2010;85(1):47-51.
135. Kim DS, Lee YH, Cho KS, Cho NH, **Chung BH**, Hong SJ. Lymphovascular invasion and pT stage are prognostic factors in patients treated with radical nephroureterectomy for localized upper urinary tract transitional cell carcinoma. *Urology*. 2010;75:328-332.
136. Chang HS, Park CH, Kim DK, Park JK, Hong SJ, **Chung BH**, Lee JG, Kim CS, Lee KS, Kim JC. Assessment of patient-reported outcome of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and treated with tamsulosin HCl in Korea. *Urology* 2010;75:1156-1161.
137. Lee SH, Park SU, Rha KH, Choi YD, Hong SJ, Yang SC, Mah SY, **Chung BH**. Trends in the incidence of benign pathological lesions at partial nephrectomy for presumed renal cell carcinoma in renal masses on preoperative computed tomography imaging: a single institute experience with 290 consecutive patients. *Int J Urol*. 2010;17:512-516.
138. Lee SH, Jung HJ, Mah SY, **Chung BH**. Renal abscesses measuring 5 cm or less: outcome of medical treatment without therapeutic drainage. *Yonsei Med J*. 2010;51:569-573.
139. Choi KH, Lee SH, Jung WS, **Chung BH**. Robot-assisted radical prostatectomy in a patient with a preexisting three-piece inflatable penile prosthesis. *Korean J Urol*. 2010;51:70-72.
140. Oh CY, Lee SH, Yoo SJ, **Chung BH**. Korean urologist's view of practice patterns in diagnosis and management of benign prostatic hyperplasia: a nationwide survey. *Yonsei Med J*. 2010;51:248-52.
141. Lee SH, Mah SY, **Chung BH**. Incidentally discovered inverted papilloma of the urinary bladder in patients with lower urinary tract symptoms. *J Endourol*. 2010;24:271-275.
142. Kim MK, Cheon J, Lee KS, Chung MK, Lee JY, Lee SW, Kim SW, **Chung BH**, Park K, Park JK. An open, non-comparative, multicentre study on the impact of alfuzosin on sexual function using the Male Sexual Health Questionnaire in patients with benign prostate hyperplasia. *Int J Clin Pract*. 2010;64:345-550.
143. Lee SH, Park KK, Mah SY, **Chung BH**. Effects of α -blocker 'add on' treatment on blood pressure in symptomatic BPH with or without concomitant hypertension. *Prostate Cancer Prostatic Dis*. 2010;13:333-337.

144. Lee JY, Lee SH, Kim SJ, Kim CS, Lee HM, Kim CI, **Chung BH**. Change in International Prostate Symptom storage subscore after long-term medical therapy in BPH patients: finasteride and alpha-blocker combination therapy in men with moderate-to-severe LUTS/BPH in Korea. *Urology* 2011;77:171-176.
145. Park KK, Lee SH, Kim JH, **Chung BH**. The effects of the period between biopsy and diffusion weighted magnetic resonance imaging on cancer staging in localized prostate cancer. *BJU Int.* 2010;106:1148-1151.
146. Park SU, Lee SH, Chung YG, Park KK, Mah SY, Hong SJ, **Chung BH**. Warm Sitz Bath : Are There Benefits after Transurethral Resection of the Prostate? *Korean J Urol.* 2010;51:763-766.
147. Lee SH, Park KK, Chung MS, **Chung BH**. Clinical Features of Familial or Hereditary Prostate Cancer in Korean Men: A Pilot Study. *Korean J Urol.* 2011;52:9-12.
148. Kim KH, Kim MU, Jeong WJ, Lee YS, Kim KH, Park KK, Chung MS, **Chung BH**, Lee SH. Incidentally detected Inguinoscrotal Bladder Hernia. *Korean J Urol.* 2011;52:71-73.
149. Lee SH, Chung MS, Chung YG, Park KK, **Chung BH**. Does Performance of robot assisted laparoscopic radical prostatectomy within 2 weeks of prostate biopsy affect the outcome? *Int J Urol.* 2011;18:141-146.
150. Park KK, Lee SH, **Chung BH**. The Effects of Long-Term Androgen Deprivation Therapy on Penile Length in Patients with Prostate Cancer: A Single-Center, Prospective, Open-Label, Observational Study. *J Sex Med.* 2011;11:3214-3219.
151. Kim DS, Chung YG, Kim DJ, Park KK, Chung MS, Lee SH, Mah SY, **Chung BH**. Optimal timing to evaluate prediagnostic baseline erectile function in patients undergoing robot assisted radical prostatectomy. *J Sex Med.* 2012;9:602-607.
152. Lee SH, **Chung BH**, Kim SJ, Kim JH, Kim JC, Lee JY. Initial combined treatment with anticholinergics and a-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. *Prostate Cancer Prostatic Dis.* 2011;14:320-325.
153. Lee DH, Lee SH, Lee DH, Chung MS, **Chung BH**. Are men who undergo radical prostatectomy with lower urinary tract symptoms at an increased risk for aggressive prostate cancer? *Korean J Urol.* 2011;52:819-823.
154. Yeom CD, Lee SH, Park SU, Park KK, **Chung BH**. Are Clinically Insignificant Prostate Cancers Really Insignificant among Korean Men? *Yonsei Med J.* 2011;53:358-362.
155. Chung MS, Lee SH, Park KK, Oh CY, **Chung BH**. Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: A multi-center, prospective, randomized study. *Int J Clin Pract.* 2011;65:1193-1199.
156. Lee SH, Oh CY, Park KK, Chung MS, Yoo SJ, **Chung BH**. Comparison of the clinical efficacy of medical treatment of symptomatic benign prostatic hyperplasia between normal and obese patients. *Asian J Androl.* 2011;13:728-731.
157. Lee JY, Lee SH, Kim SJ, Kim CS, Lee HM, Kim CI, **Chung BH**. Change in international prostate symptom storage subscore after long-term medical therapy in BPH patients: finasteride and alpha-blocker combination therapy in men with moderate-to-severe LUTS/BPH in Korea. *Urology* 2011;77:171-176.
158. Lorenzo EI, Jeong W, Oh CK, **Chung BH**, Choi YD, Rha KH. Robotics applied in laparoscopic kidney surgery: the Yonsei University experience of 127 cases. *Urology* 2011;77:114-118.
159. Yoo C, Oh CY, Cho JS, Song C, Seo SI, Ahn H, Hwang TK, Cheon J, Lee KH, Kwon TG, Jung TY, Chung MK, Lee SE, Lee HM, Lee ES, Choi YD, **Chung BH**, Kim HJ, Kim WJ, Byun SS, Choi HY. Clinical significance of a large difference (≥ 2 points) between biopsy and post-prostatectomy pathological Gleason scores in patients with prostate cancer.

2011;26:507-512.

160. Kang SG, Park CH, Kim DK, Park JK, Hong SJ, **Chung BH**, Kim CS, Lee KS, Kim JC, Lee JG. Long-term outcome of tamsulosin for patients with lower urinary tract symptoms according to the treatment response defined by lower urinary tract symptom outcomes score. *Int J Clin Pract*. 2011;65:691-697.
161. Chung MS, Lee SH, Jung HB, Park WK, **Chung BH**. Impact of a retrotrigonal layer backup stitch on post-prostatectomy incontinence. *Korean J Urol*. 2011;52:709-714.
162. Lee SH, Park KK, Yeom CD, Lee DH, **Chung BH**. Is it suitable to eliminate bone scan for prostate cancer patients with PSA \leq 20 ng/mL? *World J Urol*. 2012;30:265-269.
163. Park KK, Lee SH, Choi YD, **Chung BH**. Optimal baseline prostate-specific antigen level to distinguish risk of prostate cancer in healthy men between 40 and 69 years of age. *J Korean Med Sci*. 2012;27:40-45.
164. Lee SH, **Chung BH**, Kim CS, Lee HM, Kim CI, Yoo TK, Lee KS, Park KS, Byun SS, Yoon BI, Kim SW, Lee JY. Survey on benign prostatic hyperplasia distribution and treatment patterns for men with lower urinary tract symptoms visiting urologists at general hospitals in Korea: a prospective, noncontrolled, observational cohort study. *Urology* 2012;79:1379-1384.
165. Lee SH, Chung MS, Kim JH, Oh YT, Rha KH, **Chung BH**. Magnetic Resonance Imaging targeted biopsy in men with previously negative prostate biopsies. *J Endourol*. 2012;26:787-791.
166. Jung JH, Seo JW, Lim MS, Lee JW, **Chung BH**, Hong SJ, Song JM, Rha KH. Extended pelvic lymph node dissection including internal iliac packet should be performed during robot-assisted laparoscopic radical prostatectomy for high-risk prostate cancer. *J Laparoendosc Adv Surg Tech A*. 2012;22:785-790.
167. **Chung BH**, Lee SH, Roehrborn CG, Siami PF, Major-Walker K, Wilson TH, Montorsi F. CombAT Study Group. Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: long-term results from the combination of dutasteride and tamsulosin study. *Int J Urol*. 2012;19:1031-1035.
168. Chung MS, Lee SH, Lee DH, Kim SJ, Kim CS, Lee KS, Jung JI, Kim SW, Lee YS, **Chung BH**. Practice Patterns of Korean Urologists for Screening and Managing Prostate Cancer according to PSA Level. *Yonsei Med J*. 2012;53:1136-1141.
169. Lee DH, Jung HB, Lee SH, Rha KH, Choi YD, Hong SJ, Yang SC, **Chung BH**. Comparison of Pathological Outcomes of Active Surveillance Candidates Who Underwent Radical Prostatectomy Using Contemporary Protocols at a High-volume Korean Center. *Jpn J Clin Oncol*. 2012;42:1079-1085.
170. Chung MS, Lee SH, Lee DH, Kim SJ, Kim CS, Lee KS, Jung JI, Kim SW, Lee YS, **Chung BH**. Practice patterns of Korean urologists for screening and managing prostate cancer according to PSA level. *Yonsei Med J*. 2012;53:1136-1141.
171. Jang K, Lee DH, Lee SH, **Chung BH**. Treatment of Prostatic Abscess: Case Collection and Comparison of Treatment Methods. *Korean J Urol*. 2012;53:860-864.
172. Han HH, Ham WS, Kim JH, Hong CH, Choi YD, Han SW, **Chung BH**. Transmesocolic approach for left side laparoscopic pyeloplasty: comparison with laterocolic approach in the initial learning period. *Yonsei Med J*. 2013;54:197-203.
173. Park KK, Chung MS, Chung SY, Kim JH, **Chung BH**. Effects of post biopsy digital rectal compression on improving prostate cancer staging using magnetic resonance imaging in localized prostate cancer. *Yonsei Med J*. 2013;54:81-86.
174. Kim MS, Park KK, **Chung BH**, Lee SH. Effect of Photoselective Vaporization Prostatectomy on Lower Urinary Tract Symptoms in Benign Prostatic Hyperplasia With or Without Intravesical Prostatic Protrusion *Korean J Urol*. 2013;54:36-41.
175. Lee DH, Jung HB, Chung MS, Lee SH, **Chung BH**. The change of prostate cancer treatment in Korea: 5 year analysis of a single institution. *Yonsei Med J*. 2013;54:87-91.

176. Lee DH, Jung HB, Chung MS, Lee SH, **Chung BH**. Patent processus vaginalis in adults who underwent robot-assisted laparoscopic radical prostatectomy: Predictive signs of postoperative inguinal hernia in the internal inguinal floor. *Int J Urol*. 2013;20:177-182.
177. Chung MS, Lee SH, Lee DH, **Chung BH**. Evaluation of the 7th American Joint Committee on Cancer TNM Staging System for Prostate Cancer in Point of Classification of Bladder Neck Invasion. *Jpn J Clin Oncol*. 2013;43:184-188.
178. Kim KH, Lim SK, Kim HY, Shin TY, Lee JY, Choi YD, **Chung BH**, Hong SJ, Rha KH. Extended vs standard lymph node dissection in robot-assisted radical prostatectomy for intermediate- or high-risk prostate cancer: a propensity-score-matching analysis. *BJU Int*. 2013;112:216-223.
179. Kim KH, Lim SK, Shin TY, Lee JY, **Chung BH**, Rha KH, Hong SJ. Upgrading of Gleason score and prostate volume: a clinicopathological analysis. *BJU Int*. 2013;111:1310-1316.
180. Lee DH, Jung HB, Park JW, Kim KH, Kim J, Lee SH, **Chung BH**. Can Western based online prostate cancer risk calculators be used to predict prostate cancer after prostate biopsy for the Korean population? *Yonsei Med J*. 2013;54:665-671.
181. Kim KH, Lim SK, Shin TY, **Chung BH**, Hong SJ, Rha KH. Biochemical outcomes after robot-assisted radical prostatectomy in patients with follow-up more than 5-years. *Asian J Androl*. 2013;15:404-408.
182. Lee DH, Koo KC, Lee SH, Rha KH, Choi YD, Hong SJ, **Chung BH**. Low-risk Prostate Cancer Patients Without Visible Tumor (T1c) On Multiparametric MRI Could Qualify for Active Surveillance Candidate Even If They Did Not Meet Inclusion Criteria of Active Surveillance Protocol. *Jpn J Clin Oncol*. 2013;43:553-558.
183. Lim SK, Shin TY, Kim KH, Han WK, **Chung BH**, Hong SJ, Choi YD, Rha KH. LESS Robot-assisted Nephroureterectomy: Comparison with Conventional Multiport Technique in the Management of Upper Urinary Tract Urothelial Carcinoma. *BJU Int*. 2014;114:90-97.
184. Lim SK, Kim KH, Shin TY, **Chung BH**, Hong SJ, Choi YD, Rha KH. Yonsei Criteria: A New Protocol for Active Surveillance in the Era of Robotic and Local Ablative Surgeries. *Clin Genitourin Cancer*. 2013;11:501-507.
185. Lee DH, Koo KC, Lee SH, Rha KH, Choi YD, Hong SJ, **Chung BH**. Tumor lesion diameter on diffusion weighted magnetic resonance imaging could help predict insignificant prostate cancer in patients eligible for active surveillance: preliminary analysis. *J Urol*. 2013;190:1213-1217.
186. Kim KH, Lim SK, Shin TY, Kang DR, Han WK, **Chung BH**, Rha KH, Hong SJ. Tumor volume adds prognostic value in patients with organ-confined prostate cancer. *Ann Surg Oncol*. 2013;20:3133-3139.
187. Lim SK, Kim KH, Shin TY, **Chung BH**, Hong SJ, Choi YD, Rha KH. Gleason 5+4 has worse oncological and pathological outcomes compared with Gleason 4+5: significance of Gleason 5 pattern. *Ann Surg Oncol*. 2013;20:3127-3132.
188. Chung MS, Lee SH, Lee DH, **Chung BH**. Is small prostate volume a predictor of Gleason score upgrading after radical prostatectomy? *Yonsei Med J*. 2013;54:902-906.
189. Lee DH, Lee SH, Rha KH, Choi IY, Lee JY, Kim SW, Lee S, Hong SK, Byun SS, Jeong IG, Hong JH, Kim CS, Jeon HG, Lee HM, **Chung BH**. The Establishment of K-CaP (the Multicenter Korean Prostate Cancer Database). *Korean J Urol*. 2013;54:229-233.
190. Chung MS, Lee SH, Lee DH, Kim SJ, Kim CS, Lee KS, Jung JI, Kim SW, Lee YS, **Chung BH**. Practice patterns of Korean urologists for screening and managing prostate cancer according to PSA level. *Yonsei Med J*. 2012;53:1136-1141.
191. Lee DH, Jung HB, Lee SH, Rha KH, Choi YD, Hong SJ, Yang SC, **Chung BH**. Comparison of pathological outcomes of active surveillance candidates who underwent radical prostatectomy using contemporary protocols at a high-volume Korean center. *Jpn J Clin Oncol*. 2012;42:1079-1085.

192. Koo KC, Lee DH, Kim JH, Rha KH, **Chung BH**, Hong SJ, Mah SY. Prevalence and Management of Lower Urinary Tract Symptoms in Methamphetamine Abusers: An Under-Recognized Clinical Identity. *J Urol.* 2013 ;191:722-726.
193. Koo KC, Shim GS, Park HH, Rha KH, Choi YD, **Chung BH**, Hong SJ, Lee JW. Treatment outcomes of chemical castration on Korean sex offenders. *J Forensic Leg Med.* 2013;20:563-566.
194. Koo KC, Lee DH, Lee SH, **Chung BH**. Peripheral zone prostate-specific antigen density: an effective parameter for prostate cancer prediction in men receiving 5 α -reductase inhibitors. *Prostate Int* 2013;1:1-7.
195. Lee SH, Kim KH, Choi JH, Koo KC, Lee DH, **Chung BH**. Can microfocal prostate cancer be regarded as low-risk prostate cancer? *Prostate Int.* 2013;1:158-162.
196. Bang WJ, Oh CY, Yoo C, Cho JS, Yang DY, Lee DH, Lee SH, **Chung BH**. Efficacy and safety of the simultaneous administration of mirodenafil and an α -blocker in men with BPH-LUTS: a multicenter open-label prospective study. *Int J Impot Res.* 2013;25:149-154.
197. Lee DH, Chung DY, Lee KS, Kim IK, Rha KH, Choi YD, **Chung BH**, Hong SJ, Kim JH. Clinical experiences of incidental prostate cancer after transurethral resection of prostate (TURP) according to initial treatment: a study of a Korean high volume center. *Yonsei Med J.* 2014;55:78-83.
198. Lee DH, Koo KC, Lee SH, **Chung BH**. A simple procedure to prevent postoperative inguinal hernia after robot-assisted laparoscopic radical prostatectomy: a plugging method of the internal inguinal floor for patients with patent processus vaginalis. *J Urol.* 2014;191:468-472.
199. Lim SK, Kim KH, Shin TY, Han WK, **Chung BH**, Hong SJ, Choi YD, Rha KH. Retzius-sparing Robot-assisted Laparoscopic Radical Prostatectomy - combining the best of retropubic and perineal approaches. *BJU Int.* 2014;114:236-244.
200. Lee SH, Lee HM, Kim SW, Lee ES, Hong SJ, Kim CS, Kang TW, **Chung BH**. Is high-dose leuporelin acetate effective and safe in asian men with prostate cancer? An open-label, non-comparative, multi-center clinical trial. *Yonsei Med J.* 2014;55:310-315.
201. Jung JH, Kim HW, Oh CK, Song JM, **Chung BH**, Hong SJ, Rha KH Simultaneous robot-assisted laparoendoscopic single-site partial nephrectomy and standard radical prostatectomy. *Yonsei Med J.* 2014;55:535-538.
202. Koo KC, Lee DH, Kim JH, Rha KH, **Chung BH**, Hong SJ, Mah SY. Prevalence and management of lower urinary tract symptoms in methamphetamine abusers: an under-recognized clinical identity. *J Urol.* 2014;191:722-726.
203. Koo KC, Tuliao P, Yoon YE, **Chung BH**, Hong SJ, Yang SC, Rha KH. Robot-assisted radical prostatectomy in the Korean population: A 5-year propensity-score matched comparative analysis versus open radical prostatectomy. *Int J Urol.* 2014;21:781-785.
204. Kim KH, Lim SK, Kim HY, Han WK, Choi YD, **Chung BH**, Hong SJ, Rha KH. Yonsei nomogram to predict lymph node invasion in Asian men with prostate cancer during robotic era. *BJU Int.* 2014;113:598-604.
205. Koo KC, Lee DH, Kim KH, Lee SH, Hong CH, Hong SJ, **Chung BH**. Unrecognized kinetics of serum testosterone: impact on short-term androgen deprivation therapy for prostate cancer. *Yonsei Med J.* 2014;55:570-575.
206. Koo KC, Ahn JH, Hong SJ, Lee JW, **Chung BH**. Effects of chemical castration on sex offenders in relation to the kinetics of serum testosterone recovery: implications for dosing schedule. *J Sex Med.* 2014;11:1316-1624.
207. Komninos C, Tuliao P, Kim DK, Choi YD, **Chung BH**, Rha KH. Robot-assisted laparoendoscopic single-site partial nephrectomy with the novel da vinci single-site platform: initial experience. *Korean J Urol.* 2014;55:380-384.

208. Lim SK, Shin TY, Kim KH, Han WK, **Chung BH**, Hong SJ, Choi YD, Rha KH. Laparoendoscopic single-site (LESS) robot-assisted nephroureterectomy: comparison with conventional multiport technique in the management of upper urinary tract urothelial carcinoma. *BJU Int.* 2014;114:90-97.
209. Koo KC, Tulliao P, Yoon YE, **Chung BH**, Hong SJ, Yang SC, Rha KH. Robot-assisted radical prostatectomy in the Korean population: a 5-year propensity-score matched comparative analysis versus open radical prostatectomy. *Int. J Urol.* 2013;21:781-785.
210. Lim SK, Kim KH, Shin TY, Han WK, **Chung BH**, Hong SJ, Choi YD, Rha KH. Retzius-sparing robot-assisted laparoscopic radical prostatectomy: combining the best of retropubic and perineal approaches. *BJU Int.* 2014;114:236-244.
211. Koo KC, Yoon YE, **Chung BH**, Hong SJ, Rha KH. Analgesic opioid dose is an important indicator of postoperative ileus following radical cystectomy with ileal conduit: experience in the robotic surgery era. *Yonsei Med J.* 2014;55:1359-1365.
212. Lee SH, Kim IG, Jung AR, Shrestha KR, Lee JH, Park KD, **Chung BH**, Kim SW, Kim KH, Lee JY. Combined effects of brain-derived neurotrophic factor immobilized poly-lactic-co-glycolic acid membrane with human adipose-derived stem cells and basic fibroblast growth factor hydrogel on recovery of erectile dysfunction. *Tissue Eng Part A.* 2014;20:2446-2454.
213. Koo KC, Jung DC, Lee SH, Choi YD, **Chung BH**, Hong SJ, Rha KH. Feasibility of robot-assisted radical prostatectomy for very-high risk prostate cancer: surgical and oncological outcomes in men aged ≥ 70 years. *Prostate Int.* 2014;2:127-132.
214. Koo KC, Yoon YE, Rha KH, **Chung BH**, Yang SC, Hong SJ. Low body mass index is associated with adverse oncological outcomes following radical prostatectomy in Korean prostate cancer patients. *Int Urol Nephrol.* 2014;46:1935-1940.
215. Koo KC, Yoo H, Kim KH, Park SU, Han KS, Rha KH, Hong SJ, Yang SC, **Chung BH**. Prognostic Impact of Synchronous Second Primary Malignancies on the Overall Survival of Patients with Metastatic Prostate Cancer. *J Urol.* 2015;193:1239-44.
216. Komninos C, Shin TY, Tulliao P, Kim DK, Han WK, **Chung BH**, Choi YD, Rha KH. Renal Function is the same regardless of clamp technique 6 months after Robot-assisted Partial Nephrectomy: Analysis of Off-Clamp, Selective Arterial Clamp and Main Artery Clamp with minimum of 1 year follow-up. *BJU Int.* 2015;115:921-8.
217. Komninos C, Shin TY, Tulliao P, Kim DK, Han WK, **Chung BH**, Choi YD, Rha KH. Robotic partial nephrectomy for completely endophytic renal tumors: complications and functional and oncologic outcomes during a 4-year median period of follow-up. *Urology* 2014;84:1367-1373.
218. Koo KC, Tulliao P, Komninos C, Choi YD, **Chung BH**, Hong SJ, Jee SH, Rha KH. Prognostic impact of time to undetectable prostate-specific antigen in patients with positive surgical margins following radical prostatectomy. *Ann Surg Oncol.* 2015;22:693-700.
219. You D, **Chung BH**, Lee SE, Kim CS. Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study. *Prostate Int.* 2015;3:22-6.
220. Koo KC, Park SU, Kim KH, Rha KH, Hong SJ, Yang SC, **Chung BH**. Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levels. *Prostate Int.* 2015;3:10-5.
221. Kim do J, Lee KH, Lim SH, **Chung BH**, Song SW. Aorta Remodeling after Endovascular Treatment of a Chronic DeBakey IIIb Aneurysm and Simultaneous Palliation of a Renal Cell Carcinoma. *Korean J Thorac Cardiovasc Surg.* 2015;48:142-5.
222. Park SG, **Chung BH**, Lee SW, Park JK, Park K, Cheon J, Lee KS, Kim HJ, Seong DH, Oh SJ, Kim SW, Lee JY, Choo SH, Choi JB. Alpha-Blocker Treatment Response in Men With Lower Urinary Tract Symptoms Based on Sympathetic Activity: Prospective, Multicenter, Open-Labeled, Observational Study. *Int Neurourol J.* 2015;19:107-12.
223. Koo KC, Park SU, Rha KH, Hong SJ, Yang SC, Hong CH, **Chung BH**. Transurethral resection of the prostate for patients with

- Gleason score 6 prostate cancer and symptomatic prostatic enlargement: a risk-adaptive strategy for the era of active surveillance. *Jpn J Clin Oncol.* 2015;45:785-90.
224. Koo KC, Park SU, Kim KH, Rha KH, Hong SJ, Yang SC, **Chung BH**. Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer. *Yonsei Med J.* 2015;56:1206-12.
225. Koo KC, Lee KS, **Chung BH**. Urologic cancers in Korea. *Jpn J Clin Oncol.* 2015;45:805-11.
226. Koo KC, Park SU, Kim KH, Rha KH, Hong SJ, Yang SC, **Chung BH**. Progression to castrate resistance and cancer-specific mortality in treatment-naïve patients initially diagnosed with metastatic prostate cancer: Prognostic impacts of the site of metastasis and pain. *Yonsei Med J.* 2015;56:1206-12.
227. Lee SH, Koo KC, Lee DH, **Chung BH**. Nonvisible tumors on multiparametric magnetic resonance imaging does not predict low-risk prostate cancer. *Prostate Int.* 2015 Dec;3(4):127-31.
228. Koo KC, Lee KS, Cho KS, Rha KH, Hong SJ, **Chung BH**. Comprehensive analysis and validation of contemporary survival prognosticators in Korean patients with metastatic renal cell carcinoma treated with targeted therapy: prognostic impact of pretreatment neutrophil-to-lymphocyte ratio. *Int Urol Nephrol.* 2016 Jun;48(6):985-92.
229. Koo KC, Lee KS, Choi AR, Rha KH, Hong SJ, **Chung BH**. Diagnostic impact of dysmorphic red blood cells on evaluating microscopic hematuria: the urologist's perspective. *Int Urol Nephrol.* 2016 Jul;48(7):1021-7.
230. Kim DK, Koo KC, Abdel Raheem A, Kim KH, **Chung BH**, Choi YD, Rha KH. Single Positive Lymph Node Prostate Cancer Can Be Treated Surgically without Recurrence. *PLoS One.* 2016 Mar 31;11(3):e0152391.
231. Park YH, Kim Y, Yu H, Choi IY, Byun SS, Kwak C, **Chung BH**, Lee HM, Kim CS, Lee JY. Is lymphovascular invasion a powerful predictor for biochemical recurrence in pT3 N0 prostate cancer? Results from the K-CaP database. *Sci Rep.* 2016 May 5;6:25419.
232. Kim CS, Theeuwes A, Kwon DD, Choi YD, **Chung BH**, Lee HM, Lee KH, Lee SE. The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients. *Investig Clin Urol.* 2016 May;57(3):174-83.
233. Abdel Raheem A, Kim DK, Santok GD, Alabdulaali I, **Chung BH**, Choi YD, Rha KH. Stratified analysis of 800 Asian patients after robot-assisted radical prostatectomy with a median 64 months of follow up. *Int J Urol.* 2016 Sep;23(9):765-74.
234. Jang HS, Koo KC, Cho KS, **Chung BH**. Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer. *Yonsei Med J.* 2016 Sep;57(5):1070-8.
235. Santok GD, Abdel Raheem A, Kim LH, Chang K, Lum TG, **Chung BH**, Choi YD, Rha KH. Perioperative and short-term outcomes of Retzius-sparing robot-assisted laparoscopic radical prostatectomy stratified by gland size. *BJU Int.* 2016 Aug 18. doi: 10.
236. Akaza H, Hirao Y, Kim CS, Oya M, Ozono S, Ye D, Cooperberg M, Hinotsu S, Lee JY, Zhu G, Namiki M, Horie S, **Chung BH**, Chen CH, Fai NC, Hakim L, Chiong E, Letran J, Umbas R, Suzuki K, Nishimura K, Ong TA, Lojanapiwat B, Wu TL, Kim WJ, Murphy D, Ogawa O, Carroll P, Naito S, Tsukamoto T. Asia prostate cancer study (A-CaP Study) launch symposium. *Prostate Int.* 2016 Sep;4(3):88-96.

237. Santok GD, Raheem AA, Kim LH, Chang K, **Chung BH**, Choi YD, Rha KH. Proctorship and mentoring: Its backbone and application in robotic surgery. *Investig Clin Urol*. 2016 Dec;57
238. Santok GD, Abdel Raheem A, Kim LH, Chang K, Lum TG, **Chung BH**, Choi YD, Rha KH. Prostate-specific antigen 10-20 ng/mL: A predictor of degree of upgrading to ≥ 8 among patients with biopsy Gleason score 6. *Investig Clin Urol*. 2017 Mar;58(2):90-97.
239. Koo KC, Cho JS, Bang WJ, Lee SH, Cho SY, Kim SI, Kim SJ, Rha KH, Hong SJ, **Chung BH**. Cancer-Specific Mortality Among Korean Men with Localized or Locally Advanced Prostate Cancer Treated with Radical Prostatectomy Versus Radiotherapy: A Multi-Center Study Using Propensity Scoring and Competing Risk Regression Analyses. *Cancer Res Treat*. 2018 Jan;50(1):129-137.
240. Lee KS, Koo KC, Choi IY, Lee JY, Hong JH, Kim CS, Lee HM, Hong SK, Byun SS, Rha KH, **Chung BH**. Re-stratification of Patients with High-Risk Prostate Cancer According to the NCCN Guidelines among Patients Who Underwent Radical Prostatectomy: An Analysis Based on the K-CaP Registry. *Cancer Res Treat*. 2018 Jan;50(1):88-94.
241. Lee KS, Koo KC, Cho KS, Lee SH, Han WK, Choi YD, Hong SJ, Park SU, Lee SY, Ko WJ, Kim YS, **Chung BH**. Indications for a second prostate biopsy in patients suspected with prostate cancer after an initial negative prostate biopsy. *Prostate Int*. 2017 Mar;5(1):24-28.
242. Park YH, Kim TH, Lee SW, **Chung BH**, Cho JS, Lee JY. Treatment Patterns and Patient Reported Outcomes in Benign Prostatic Hyperplasia Patients with Overactive Bladder Symptoms. *Low Urin Tract Symptoms*. 2017 May;9(2):75-81.
243. Yoo S, Hong JH, Byun SS, Lee JY, **Chung BH**, Kim CS. Is suspicious upstaging on multiparametric magnetic resonance imaging useful in improving the reliability of Prostate Cancer Research International Active Surveillance (PRIAS) criteria? Use of the K-CaP registry. *Urol Oncol*. 2017 Jul;35(7):459.e7-459.e13.
244. Gillissen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, **Chung BH**, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothesis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. *Eur Urol*. 2018 Feb;73(2):178-211.
245. Lee KS, Koo KC, Lee SH, Cho KS, Hong CH, **Chung BH**. Effect of Climatic Parameters on Acute Urinary Retention Incidence. *Low Urin Tract Symptoms*. 2017 Jul 13.
246. Kim CS, Lee JY, **Chung BH**, Kim WJ, Fai NC, Hakim L, Umbas R, Ong TA, Lim J, Letran JL, Chiong E, Wu TL, Lojanapiwat B, Türkeri L, Murphy DG, Gardiner RA, Moretti K, Cooperberg M, Carroll P, Mun SK, Hinotsu S, Hirao Y, Ozono S, Horie S, Onozawa M, Kitagawa Y, Kitamura T, Namiki M, Akaza H. Report of the Second Asian Prostate Cancer (A-CaP) Study Meeting. *Prostate Int*. 2017 Sep;5(3):95-103.

247. Lee KS, Koo KC, **Chung BH**. The impact of a family history of prostate cancer on the prognosis and features of the disease in Korea: results from a cross-sectional longitudinal pilot study. *Int Urol Nephrol*. 2017 Dec;49(12):2119-2125.
248. Lee KS, Koo KC, **Chung BH**. Long-Term Results of the Plugging Method with Regard to the Prevention of a Postoperative Inguinal Hernia After Robot-Assisted Laparoscopic Prostatectomy: A Retrospective Study. *J Endourol*. 2017 Nov;31(11):1183-1188.
249. Koo KC, Lee KS, Jeong JY, Choi IY, Lee JY, Hong JH, Kim CS, Lee HM, Hong SK, Byun SS, Lee SH, Rha KH, **Chung BH**. Pathological and oncological features of Korean prostate cancer patients eligible for active surveillance: analysis from the K-CaP registry. *Jpn J Clin Oncol*. 2017 Oct 1;47(10):981-985.
250. Kim LHC, Santok GD, Raheem AA, Chang K, Lum T, **Chung BH**, Choi YD, Rha KH. Retzius-sparing robot-assisted radical prostatectomy is safe for patients with prior transurethral prostate surgery. *Int Braz J Urol*. 2017 Nov 17;43.
251. Lee KS, Koo KC, **Chung BH**. Risk and Management of Postoperative Urinary Retention Following Spinal Surgery. *Int Neurourol J*. 2017 Dec;21(4):320-328.
252. Shim KH, Kim TW, **Chung BH**, Lee SW, Park JK, Park K, Cheon J, Lee KS, Kim HJ, Seong DH, Oh SJ, Kim SW, Lee JY, Choo SH, Choi JB. Changes in autonomic nervous system activity after treatment with alpha-blocker in men with lower urinary tract symptoms. *Investig Clin Urol*. 2018 Jan;59(1):49-54.
253. Heo JE, Ahn HK, Kim J, **Chung BH**, Lee KS. Changes in Clinical Characteristics of Patients with an Initial Diagnosis of Prostate Cancer in Korea: 10-Year Trends Reported by a Tertiary Center. *J Korean Med Sci*. 2018 Feb 5;33(6):e42.
254. Lee JS, Lee HS, Ha JS, Han KS, Rha KH, Hong SJ, **Chung BH**, Koo KC. Subcutaneous Fat Distribution is a Prognostic Biomarker for Men with Castration Resistant Prostate Cancer. *J Urol*. 2018 Jan 31.
255. Park JS, Lee KS, Ham WS, **Chung BH**, Koo KC. Impact of metformin on serum prostate-specific antigen levels: Data from the national health and nutrition examination survey 2007 to 2008. *Medicine (Baltimore)*. 2017 Dec;96(51):e9427
256. Koo KC, Yoon JH, Park NC, Lee HS, Ahn HK, Lee KS, Kim DK, Cho KS, **Chung BH**, Hong CH. The Impact of Preoperative α -Adrenergic Antagonists on Ureteral Access Sheath Insertion Force and the Upper Limit of Force Required to Avoid Ureteral Mucosal Injury: A Randomized Controlled Study. *J Urol*. 2018 Jun;199(6):1622-1630.
257. Heo JE, Koo KC, Hong SJ, Park SU, **Chung BH**, Lee KS. Prostate-Specific Antigen Kinetics Following 5 α -Reductase Inhibitor Treatment May Be a Useful Indicator for Repeat Prostate Biopsy. *Yonsei Med J*. 2018 Mar;59(2):219-225.
258. Lee KS, Koo KC, **Chung BH**. Quantitation of hypoechoic lesions for the prediction and Gleason grading of prostate cancer: a prospective study. *World J Urol*. 2018 Mar 5
259. Chang KD, Abdel Raheem A, Kim KH, Oh CK, Park SY, Kim YS, Ham WS, Han WK, Choi YD, **Chung BH**, Rha KH. Functional and oncological outcomes of open, laparoscopic and robot-assisted partial nephrectomy: a multicentre comparative matched-pair analyses with a median of 5 years' follow-up. *BJU Int*. 2018 Apr 12.
260. Chang KD, Abdel Raheem A, Choi YD, **Chung BH**, Rha KH. Retzius-sparing robot-assisted radical prostatectomy using the Revo-i robotic surgical system: surgical technique and results of the first human trial. *BJU Int*. 2018 Apr 12.

261. Koo KC, Lee JS, Kim JW, Han KS, Lee KS, Kim DK, Ha YS, Rha KH, Hong SJ, **Chung BH**. Impact of clinical trial participation on survival in patients with castration-resistant prostate cancer: a multi-center analysis. *BMC Cancer*. 2018 Apr 26;18(1):468.
262. Huh JS, **Chung BH**, Hong CH, Ryu JK, Kim JH, Han WK, Park KK. The effects of testosterone replacement on penile structure and erectile function after long-term castration in adult male rats. *Int J Impot Res*. 2018 May 4.
263. Kim JK, Choi MJ, Lee JS, Hong JH, Kim CS, Seo SI, Jeong CW, Byun SS, Koo KC, **Chung BH**, Park YH, Lee JY, Choi IY. A Deep Belief Network and Dempster-Shafer-Based Multiclassifier for the Pathology Stage of Prostate Cancer. *J Healthc Eng*. 2018 Mar 19;2018:4651582.
264. Lee, K. S., Koo, K. C., Lee, S. H., Cho, K. S., Hong, C. H., & **Chung, B. H.** (2018). Effect of Climatic Parameters on Acute Urinary Retention Incidence. *LUTS: Lower Urinary Tract Symptoms*, 10(3), 297-302.
265. Kim, L. H., Santok, G. D., Raheem, A. A., Chang, K., Lum, T., **Chung, B. H.**, ... & Rha, K. H. (2018). Retzius-sparing robot-assisted radical prostatectomy is safe for patients with prior transurethral prostate surgery. *International braz j urol*, 44(4), 842-843.
266. Lee, J. S., Lee, H. S., Ha, J. S., Han, K. S., Rha, K. H., Hong, S. J., **Chung, B. H.**, & Koo, K. C. (2018). Subcutaneous Fat Distribution is a Prognostic Biomarker for Men with Castration Resistant Prostate Cancer. *The Journal of urology*, 200(1), 114-120.
267. Koo, K. C., Yoon, J. H., Park, N. C., Lee, H. S., Ahn, H. K., Lee, K. S., **Chung, B. H.**, ... & Hong, C. H. (2018). The Impact of Preoperative α -Adrenergic Antagonists on Ureteral Access Sheath Insertion Force and the Upper Limit of Force Required to Avoid Ureteral Mucosal Injury: A Randomized Controlled Study. *The Journal of urology*, 199(6), 1622-1630.
268. Lee, K. S., Koo, K. C., & **Chung, B. H.** (2018). Quantitation of hypoechoic lesions for the prediction and Gleason grading of prostate cancer: A prospective study. *World journal of urology*, 1-7.
269. Ban, T. H., Min, J. W., Seo, C., Kim, D. R., Lee, Y. H., **Chung, B. H.**, ... & Choi, B. S. (2018). Update of aristolochic acid nephropathy in Korea. *The Korean journal of internal medicine*, 33(5), 961.
270. Chang, K. D., Abdel Raheem, A., Kim, K. H., Oh, C. K., Park, S. Y., Kim, Y. S., **Chung, B. H.**, ... & Rha, K. H. (2018). Functional and oncological outcomes of open, laparoscopic and robot-assisted partial nephrectomy: a multicentre comparative matched-pair analyses with a median of 5 years' follow-up. *BJU international*.
271. Chang, K. D., Abdel Raheem, A., Choi, Y. D., **Chung, B. H.**, & Rha, K. H. (2018). Retzius-sparing robot-assisted radical prostatectomy using the Revo-i robotic surgical system: surgical technique and results of the first human trial. *BJU international*.
272. Huh, J. S., **Chung, B. H.**, Hong, C. H., Ryu, J. K., Kim, J. H., Han, W. K., & Park, K. K. (2018). The effects of testosterone replacement on penile structure and erectile function after long-term castration in adult male rats. *International journal of impotence research*, 1.
273. Chiong, E., Murphy, D. G., Akaza, H., Buchan, N. C., **Chung, B. H.**, Kanesvaran, R., ... & Ong, T. (2018). Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017. *BJU international*.

274. Kim, J. W., Kim, Y. S., Ko, W. J., Choi, Y. D., Hong, S. J., Chung, B. H., & Lee, K. S. (2018). Prognostic Factors of Penile Cancer and the Efficacy of Adjuvant Treatment after Penectomy: Results from a Multi-institution Study. *Journal of Korean medical science*, 33(37).
275. Jeong, C. W., Kang, M., Jung, S. I., Kim, T. H., Park, S. W., Joung, J. Y., Chung, B. H., ... & Ahn, H. (2018). Importance of androgen-deprivation therapy during enzalutamide treatment in men with metastatic castration-resistant prostate cancer following chemotherapy: results from retrospective, multicenter data. *Prostate cancer and prostatic diseases*, 1.
276. Abdel Raheem, A., Chang, K. D., Alenzi, M. J., Lum, T. G., Ham, W. S., Han, W. K., Chung, B. H., ... & Rha, K. H. (2018). Robot-Assisted Partial Nephrectomy for Totally Endophytic Renal Tumors: Step by Step Standardized Surgical Technique and Long-Term Outcomes with a Median 59-Month Follow-Up. *Journal of Laparoendoscopic & Advanced Surgical Techniques*.
277. Hah, Y. S., Lee, K. S., Choi, I. Y., Lee, J. Y., Hong, J. H., Kim, C. S., ... Chung, B. H., & Koo K. C. (2018). Effects of age and comorbidity on survival vary according to risk grouping among patients with prostate cancer treated using radical prostatectomy: A retrospective competing-risk analysis from the K-CaP registry. *Medicine*, 97(42).
278. Lee, K. S., Koo, K. C., & Chung, B. H. (2018). Prediction of biochemical failure using prostate-specific antigen half-life in patients with adverse pathologic features after radical prostatectomy. *World Journal of Urology*, 1-8.
279. Kim, D. K., Koo, K. C., Lee, K. S., Hah, Y. S., Rha, K. H., Hong, S. J., & Chung, B. H. (2018). Time to Disease Recurrence Is a Predictor of Metastasis and Mortality in Patients with High-risk Prostate Cancer Who Achieved Undetectable Prostate-specific Antigen Following Robot-assisted Radical Prostatectomy. *Journal of Korean medical science*, 33(45).
280. Ahn, H. K., Koo, K. C., Chung, B. H., & Lee, K. S. (2018). Comparison of the delta neutrophil index with procalcitonin, erythrocyte sedimentation rate, and C-reactive protein as predictors of sepsis in patients with acute prostatitis. *Prostate International*.
281. Kim, D. K., Lee, J. S., Jung, J. H., Hah, Y. S., Koo, K. C., Lee, K. S., Chung, B. H., & Cho, K. S. (2019). What is the most effective local anesthesia for transrectal ultrasonography-guided biopsy of the prostate? A systematic review and network meta-analysis of 47 randomized clinical trials. *Scientific Reports*.
282. Ali, R., Chang, K. D., Mohammed, J., Trenton G., Ham, W. S., Han, W. K., Chung, B. H., Choi, Y. D., & Rha, K. H. (2019). Robot-Assisted Partial Nephrectomy for Totally Endophytic Renal Tumors: Step by Step Standardized Surgical Technique and Long-Term Outcomes with a Median 59-Month Follow-Up. *Journal of Laparoendoscopic & Advanced Surgical Techniques and Videoscopy*.
283. Lee, K. S., Kim, D.K., Kim, K. H., Bang, W. J., Kim, H.J., Park, S. Y., Rha, K. H., Chung, B. H., Cho, J. S., & Koo, K.C. (2019). Predictive factors for the development of renal insufficiency following partial nephrectomy and subsequent renal function recovery: A multicenter retrospective study. *Medicine*, 98(18).
284. Lee, K. S., Koo, K. C., & Chung, B. H. (2019). Prediction of biochemical failure using prostate-specific antigen half-life in patients with adverse pathologic features after radical prostatectomy. *World Journal of Urology*, 37:1321–1328
285. Chung, M. S., Shim, M. S., Cho, J. S. ..., Chung, B. H., & Lee, S. H. (2019). Pathological Characteristics of Prostate Cancer in Men Aged < 50 Years Treated with Radical Prostatectomy: a Multi-Centre Study in Korea. *Journal of Korean medical science*, 34(10)

286. Kim, D. K., Hah, Y. S., Kim, J. W., Koo, K. C., Lee, K. S., Hong, C. H., Chung, B. H., & Cho, K. S. (2019). Is Pelvic Plexus Block Superior to Periprostatic Nerve Block for Pain Control during Transrectal Ultrasonography-Guided Prostate Biopsy? A Double-Blind, Randomized Controlled Trial. *Journal of Clinical Medicine*.
287. Chi, K., Agarwal, N., Bjartell, A., Chung, B. H., ..., Ye, D., & Deprince, K. (2019). Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. *The New England Journal of Medicine*.
288. Argarwal, N., McQuarrie, K., Bjartell, A., Chowdhury, S., Chung, B. H., ..., Gitlitz, A., & Kim, N. (2019). Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. *Lancet Oncol*.
299. Park, Jee Soo; Koo, Kyo Chul; Kim, Hye Kyung; Chung, Byung Ha & Lee, Kwang Suk. (2019). Impact of metabolic syndrome-related factors on the development of benign prostatic hyperplasia and lower urinary tract symptoms in Asian population. *Medicine*.
300. Seung Il Jung, Myung Soo Kim, Chang Wook Jeong, Cheol Kwak, Sung Kyu Hong, Seok Ho Kang, Jae Young Joung, Seung Hwan Lee, Seok Joong Yun, Tae-Hwan Kim, Sung Woo Park, Seong Soo Jeon, Minyong Kang, Ji Youl Lee, Byung Ha Chung, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim, and Dong Deuk Kwon. (2019). Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting. *Investing Clin Urol*.
301. Chi, K. N., Agarwal, N., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., Juárez Soto, Á., Merseburger, A. S., Özgüroğlu, M., Uemura, H., Ye, D., Deprince, K., Naini, V., Li, J., Cheng, S., Yu, M. K., Zhang, K., Larsen, J. S., McCarthy, S., Chowdhury, S., ... TITAN Investigators (2019). Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. *N Engl J Med*
302. Chiong, E., Murphy, D. G., Akaza, H., Buchan, N. C., Chung, B. H., Kanesvaran, R., Khochikar, M., Letran, J., Lojanapiwat, B., Ng, C. F., Ong, T., Pu, Y. S., Saad, M., Schubach, K., Türkeri, L., Umbas, R., Le Chuyen, V., Williams, S., Ye, D. W., ANZUP Cancer Trials Group, ... Davis, I. D. (2019). Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017. *BJU Int*.
303. van der Kwast, T. H., Helleman, J., Nieboer, D., Bruinsma, S. M., Roobol, M. J., Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium, Trock, B., Ehdaie, B., Carroll, P., Filson, C., Kim, J., Logothetis, C., Morgan, T., Klotz, L., Pickles, T., Hyndman, E., Moore, C. M., Gnanapragasam, V., Van Hemelrijck, M., Dasgupta, P., Chung BH, ... Helleman, J. (2019). Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. *Eur Urol Oncol*.
304. Park, J. S., Koo, K. C., Choi, I. Y., Lee, J. Y., Hong, J. H., Kim, C. S., Lee, H. M., Hong, S. K., Byun, S. S., Rha, K. H., Chung, B. H., & Lee, K. S. (2019). Stratification based on adverse laboratory/pathological features for predicting overall survival in patients undergoing radical prostatectomy: A K-CaP registry-based analysis. *Medicine*.
304. Hah, Y. S., Lee, J. S., Rha, K. H., Hong, S. J., Chung, B. H., & Koo, K. C. (2019). Effect of Prior Local Treatment and Prostate-Specific Antigen Kinetics during Androgen-Deprivation Therapy on the Survival of Castration-Resistant Prostate Cancer. *Sci Rep*.

305. Kim, T. J., Yu, Y. D., Park, D. S., Rha, K. H., Hong, S. J., Cho, K. S., **Chung, B. H.**, & Koo, K. C. (2019). Impact of Cerebrovascular Disease on Survival Benefits from Local Treatment in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer. *Yonsei Med J*.
306. Park, J. S., Koo, K. C., **Chung, B. H.**, & Lee, K. S. (2019). Is targeted biopsy really needed when performing systematic prostate biopsy to raise the detection rate for prostate cancer in patients with prostate-specific antigen ≤ 10 ng/mL?. *Medicine*.
307. Kim, K. H., Lee, S. H., Kim, S. I., **Chung, B. H.**, Koo, K. C., Cho, J. S., Bang, W. J., Park, J. Y., & Hong, S. J. (2019). The Association of A Number of Predictive Factors for The Recurrence of Papillary Urothelial Neoplasm of Low Malignant Potential: Prognostic Analysis From Multiple Academic Centers. *Urol J*.
308. Koo, K. C., Lee, J. S., Ha, J. S., Han, K. S., Lee, K. S., Hah, Y. S., Rha, K. H., Hong, S. J., & **Chung, B. H.** (2019). Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio. *World J Urol*.
309. Park, J. S., Ham, W. S., Hong, C. H., **Chung, B. H.**, & Koo, K. C. (2019). The association of depression with lower urinary tract symptoms: data from the National Health and Nutrition Examination Survey, 2005-2008. *PeerJ*,
310. Park, J. S., Koo, K. C., **Chung, B. H.**, & Lee, K. S. (2019). The association of family history of prostate cancer with the diagnosis of clinically significant prostate cancer in Korean population. *Investig Clin Urol*.
311. Jung, S. I., Kim, M. S., Jeong, C. W., Kwak, C., Hong, S. K., Kang, S. H., Joung, J. Y., Lee, S. H., Yun, S. J., Kim, T. H., Park, S. W., Jeon, S. S., Kang, M., Lee, J. Y., Chung, B. H., Hong, J. H., Ahn, H., Kim, C. S., & Kwon, D. D. (2020). Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting. *Investig Clin Urol*
312. **Chung BH**, Horie S, Chiong E. (2020). Clinical studies investigating the use of leuprorelin for prostate cancer in Asia. *Prostate Int*.
313. Park, S., Kim, K., Ahn, H. K., Kim, J. W., Min, G., **Chung, B. H.**, & Koo, K. C. (2020). Impact of Lifestyle Intervention for Patients with Prostate Cancer. *Am J Health Behav*.
314. Park, J. S., Lee, D., Koo, K. C., **Chung, B. H.**, & Lee, K. S. (2020). The role of prostatic apex shape in voiding symptoms and urine flow: an exploratory and confirmatory study. *World J Urol*.
315. Uemura, H., Ye, D., Kanesvaran, R., Chiong, E., Lojanapiwat, B., Pu, Y. S., Rawal, S. K., Abdul Razack, A. H., Zeng, H., **Chung, B. H.**, Md Yusoff, N. A., Ohyama, C., Kim, C. S., Leewansangtong, S., Tsai, Y. S., Liu, Y., Liu, W., van Kooten Losio, M., & Asinas-Tan, M. (2020). United in Fight against prostate cancer (UFO) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia. *BJU Int*.
316. Oh, K. T., Koo, K. C., **Chung, B. H.**, & Lee, K. S. (2020). Comparison of prostate cancer detection rates of various prostate biopsy methods for patients with prostate-specific antigen levels of < 10.0 ng/mL in real-world practice. *Investig Clin Urol*.

317. Koo, K. C., Lee, K. S., Kim, S., Min, C., Min, G. R., Lee, Y. H., Han, W. K., Rha, K. H., Hong, S. J., Yang, S. C., & **Chung, B. H.** (2020). Long short-term memory artificial neural network model for prediction of prostate cancer survival outcomes according to initial treatment strategy: development of an online decision-making support system. *World J Urol*.
318. Ahn, H. K., Lee, K. S., Kim, D., Rha, K. H., Hong, S. J., **Chung, B. H.**, & Koo, K. C. (2020). Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy. *Yonsei Med J*.
319. Lim, B., Lee, K. S., Lee, Y. H., Kim, S., Min, C., Park, J. Y., Lee, H. S., Cho, J. S., Kim, S. I., **Chung, B. H.**, Kim, C. S., & Koo, K. C. (2020). External Validation of the Long Short-Term Memory Artificial Neural Network-Based SCaP Survival Calculator for Prediction of Prostate Cancer Survival. *Cancer Res Treat*.